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Abstract 
Background: Though we know that psychological interventions for adults with chronic 
pain are effective, many unanswered questions remain. In particular, we have a poor 
understanding of how some aspects of treatment, such as treatment ‘dose’, relate to 
outcome. We also know little about the contribution of specific components included in 
broad treatment packages, such as CBT.  
Objectives: I replicated Williams, Eccleston and Morley’s (2012) Cochrane review of 
psychological interventions for adults with non-cancer chronic pain (excluding headache) 
but extended this in two ways: I investigated the relationship between dose and outcome, 
and developed a system of categorising treatment content across trials. 
Results: 64 randomised controlled trials (N = 7,840 participants) were included. Effect sizes 
(standardised mean differences) were calculated and used in meta-analysis to explore five 
outcome domains: pain experience, pain behaviour, emotional functioning, and coping and 
cognitive appraisal. My findings converge with previous reviews; psychological 
interventions were effective, but effect sizes were relatively small.  
Meta-regression analyses found limited evidence for the moderating role of treatment ‘dose’ 
on outcome. There was some evidence that the period over which treatment was delivered 
(i.e. ‘dose in weeks’), may be related to outcome for two out of five outcome domains.  
In terms of treatment content, trials that appeared to utilise the same broad treatment 
package (e.g. CBT), often appeared to feature different treatment components. Moreover, 
treatments described as being distinct (e.g. ACT and CBT) often used similar treatment 
components. 
Conclusions: The relationship between treatment dose and outcome is complex and 
dependent on the outcome being assessed. Broad labels of treatment types, such as CBT, are 
vague and do not represent homogenous groups.  
This suggests that all treatment components are not created equal. I propose single-case 
design and patient-level data analysis as tools to help further explore treatment components, 
including treatment dose, and outcome.   
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1 Introduction 
1.1 Overview 
Chronic pain is one of the leading causes of disability worldwide. Psychological 
interventions are a well-established, and nationally recommended, element of treatments for 
chronic pain. Researchers have typically focused on whether psychological interventions are 
effective in their aims of improving functioning and reducing distress. We now have a 
diverse body of literature that has investigated the effectiveness of these interventions, the 
findings of which converge to suggest that psychological interventions do indeed improve 
functioning and reduce distress. However, many unanswered questions remain. For 
instance, we still know little about whether some components of treatment are more 
important than others in their ability to bring about a greater magnitude of change. One such 
component that may be important is the amount of treatment delivered, or treatment ‘dose’. 
My thesis aims to fill this gap by exploring the relationship between key treatment 
components such as dose of therapy, and the extent of improvement for a variety of 
outcomes.  
1.2 Background  
In this section, I will define chronic pain and present a brief history of our 
theoretical understanding of chronic pain before discussing psychological treatments for 
chronic pain in practice.  
1.2.1 Defining chronic pain  
Pain can be understood as a vital warning to potential harm, ultimately promoting 
survival. Despite the utility of short-term pain for safety, many individuals experience pain 
that is chronic. Chronic pain persists longer than the typical healing process, which is 
commonly defined as longer than three months. Such pain is increasingly called ‘persistent 
pain’ in clinical practice. To be consistent with the terminology used in research literature, I 
will use the term ‘chronic pain’. Chronic pain often causes high levels of distress and 
disability, while offering little or no protective function (Kerns, Sellinger, & Goodin, 2011). 
Those living with chronic pain must negotiate significant declines in physical, social and 
emotional functioning. Living with pain not only interferes with one’s ability to complete 
tasks effectively, but is also a threat to one’s self identity as one must adjust to increasing 
limitations in functioning (Morley, 2008). Recent definitions of chronic pain are 
increasingly recognising the complex and debilitating nature of pain. For example, Williams 
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and Craig (2016) proposed a definition of chronic pain as “a distressing experience 
associated with actual or potential tissue damage with sensory, emotional, cognitive and 
social components” (p. 2).  
The importance of chronic pain as a health condition is well-established. Indeed, 
chronic pain has been identified as one of the leading causes of disability across the world, 
and a global health priority (Goldberg & McGee, 2011). Although prevalence estimates of 
chronic pain vary between studies, it is widely recognised that chronic pain is a problem for 
many individuals worldwide. For example, a review of 19 studies and 65 surveys across 34 
countries found that the global prevalence of chronic pain was 30.3% (SD = 11.7%; Elzahaf, 
Tashani, Unsworth, & Johnson, 2012). Moreover, this number is only set to rise; with an 
ageing population and older people being more likely to experience chronic pain (Molton & 
Terrill, 2014), effective treatments for chronic pain remain high on the research and clinical 
agenda.  
1.2.2 Toward a biopsychosocial understanding of chronic pain 
Historically, chronic pain researchers held a unidimensional conceptualisation of 
pain, with treatment based upon the traditional biomedical approach (Gatchel, Peng, Peters, 
Fuchs, & Turk, 2007). The Gate Control Theory of Pain (Melzack & Wall, 1965) was a 
multidimensional attempt to understand complex aspects of chronic pain, such as the fact 
that pain can persist long after damaged tissue has healed and that the location of pain can 
change over time. The Gate Control Theory of Pain understands the experience of pain as 
the end result of a combination of cognitive-evaluative, motivational and sensory features. 
This theory prompted a surge in research into chronic pain as researchers sought to better 
understand pain mechanisms.  
Continued research, coupled with advances in neuroscientific methodology, has 
meant that a biopsychosocial model of chronic pain is now widely accepted as a way to 
understand and treat chronic pain (Gatchel et al., 2007). This model places pain as the 
outcome of a dynamic and complex interaction between physiological, psychological and 
social factors. In line with our increasingly holistic theoretical conceptualisation of chronic 
pain, clinical management of chronic pain has evolved to be multi-modal. In recognising 
that an individual’s experience of pain brings together biological, social and psychological 
factors, a biomedical treatment approach is insufficient. Rather, an interdisciplinary pain 
management approach has been recommended, and almost universally adopted (Gatchel, 
McGeary, McGeary, & Lippe, 2014).  
1.2.3 Psychological treatments for chronic pain  
Psychological treatments have been part of an inter-disciplinary framework since 
the 1970s, with an initial focus on behavioural pain management strategies (Fordyce, 1976). 
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Since then, cognitive interventions have been added to treatment protocols. The popularity 
of such interventions has meant that the most comprehensively evaluated treatment for 
chronic pain is Cognitive Behavioural Therapy (CBT). The aim of CBT for chronic pain is 
to help patients replace maladaptive cognitions and behaviours with more adaptive ones. 
Over the past 20 years a range of other psychological treatments have grown in popularity 
and become more frequently used. For example, the development of ‘third wave’ CBT 
techniques have added even greater diversity to the study of psychological interventions for 
chronic pain. Acceptance and Commitment Therapy (ACT) is an example of a third wave 
intervention that has grown in popularity within research trials for chronic pain (Veehof, 
Oskam, Schreurs, & Bohlmeijer, 2011). The aim of ACT is to help the patient to accept 
difficult thoughts and feelings, and rather than trying to replace them, making ‘committed 
action’ to do things that are personally important or meaningful. Although ACT and CBT 
are the most commonly used treatments by psychologists in clinical practice (Fenton, 2010), 
a number of alternative treatments are also used by clinicians and researchers, including 
biofeedback, relaxation, mindfulness, and coping skills training. Kerns et al. (2011) 
reviewed these interventions, highlighting that the field of psychology has been “at the 
forefront of scientific investigations of pain” (p. 428), and that we have a wide range of 
psychological interventions.  
With such a broad range of psychological interventions being studied through 
scientific investigation, we now have a wealth of research investigating treatment efficacy. 
That is, whether the treatment has an impact on outcome (Nathan, Stuart, & Dolan, 2000). 
This research has provided an opportunity to look across trials and test whether particular 
interventions continue to have efficacy when their results are combined with those from 
different studies. One approach to evaluating whether treatments are broadly efficacious is 
to synthesise outcome data from multiple trials using meta-analytic techniques.  
1.3 Evidence-Based Psychological Interventions for Chronic Pain  
Meta-analysis is the process of using statistical methods to summarise and combine 
the results of independent studies (Liberati et al., 2009). Throughout this thesis I will refer 
to meta-analytic studies as ‘secondary studies’ and the individual studies that are included in 
meta-analyses as ‘primary studies’. Meta-analysis allows researchers to combine outcomes 
from different measures by calculating an effect size for each outcome. In clinical trials, we 
can think of an effect size as an attempt to quantify the magnitude of change that is brought 
about by the intervention. In this section, I provide a brief overview of the meta-analyses 
that have investigated the evidence-base for psychological interventions for chronic pain. As 
meta-analytic techniques are only as good as the reporting of interventions in primary 
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studies, I will then discuss what the findings can tell us about the content of psychological 
interventions.  
1.3.1 Building an evidence base through meta-analyses  
Table 1.1 summarises key characteristics of the meta-analyses that have been 
completed in the field of psychological interventions for chronic pain in adults. To my 
knowledge, there have been 21 meta-analyses in total. The mean number of studies included 
across the meta-analyses is relatively small (n = 24), but the range is large (Range = 2 – 65). 
Most meta-analyses have focused on a particular type of chronic pain. The most frequently 
studied is back pain (n = 6), followed by fibromyalgia (n = 4). There have been six meta-
analyses that have not been restricted to a particular type of chronic pain, three of which 
were Cochrane reviews. In addition to focusing on a particular type of pain, most also focus 
on reviewing a particular type of intervention. Multidisciplinary rehabilitation was the most 
commonly studied type of  intervention (n = 4). Three meta-analyses considered 
psychological interventions alongside other non-medical interventions, such as 
physiotherapy. Seven meta-analyses investigated any type of psychological intervention. 
Looking across all meta-analyses, then, we can see that there is striking variability in the 
specificity of meta-analyses; some exploring a particular type of intervention for a particular 
type of chronic pain (i.e. chronic pain diagnoses), while others are more comprehensive, 
exploring any type of treatment for any type of chronic pain. The three most comprehensive 
meta-analyses are Cochrane reviews.  
On the whole, the meta-analyses support the beneficial effect of psychological 
interventions. This is especially true when they are compared to wait list or treatment as 
usual control groups. The exception to this was Karjalainen et al. (2000), who found no 
quantifiable benefits for multidisciplinary rehabilitation in their analyses of seven low 
quality trials. Typically reported effect sizes were generally small to moderate, and were 
smaller when comparing two active interventions. This pattern is similar to those observed 
across psychotherapeutic interventions more generally (Luborsky et al., 2006; Luborsky, 
Singer, & Luborsky, 1975). Effect sizes also got smaller over time; with the strongest effect 
being noted immediately following treatment, and smaller effects, although often not 
completely diminished effects, observed at follow-up.  
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Table 1.1. Overview of meta-analyses exploring psychological interventions for chronic 
pain. 
First Author* Year 
No. 
Studies 
Included 
Chronic Pain 
Diagnosis 
Type of Psychological 
Intervention  
Malone 1988 48 Chronic pain 
 
Non-medical treatments for 
chronic pain 
Flor 1992 65 Back pain Multidisciplinary treatments 
Morley (CR) 1999 25 Chronic pain Psychological interventions  
 
Karjalainen (CR) 2000 7 Fibromyalgia and 
musculoskeletal pain  
Multidisciplinary 
rehabilitation  
Karjalainen (CR) 2003a 2 Neck and shoulder 
pain 
Multidisciplinary 
rehabilitation 
Karjalainen (CR) 2003b 2 
 
Low back pain Multidisciplinary 
rehabilitation 
Hoffman  2007 22 Low back pain Psychological interventions  
 
Dixon 2007 27 Arthritis Psychological interventions 
Eccleston (CR) 2009 40 
 
Chronic pain 
 
Psychological interventions  
 
Hauser 2009 9 Fibromyalgia Multicomponent treatment 
Glombiewski  2010 23 Fibromyalgia Psychological interventions  
Henschke 2010 30 Low back pain Behavioural interventions  
Bernardy 2010 14 Fibromyalgia  CBT 
Williams (CR) 2012 35 Chronic pain Psychological interventions 
Cheong (CR) 2014 21 Pelvic pain 
 
Non-surgical interventions 
Kamper (CR) 2014 41 
 
Low back pain Multidisciplinary 
rehabilitation  
van Dessel (CR) 2014 21 
 
Medically 
unexplained pain 
Non-pharmacological 
interventions 
Monticone (CR) 2015 10 Neck pain CBT 
Pike 2016 14 Chronic pain Psychological interventions 
Veehof  2016 25 Chronic pain Acceptance & mindfulness-
based interventions 
Sielski  2017 21 Back pain Biofeedback 
CR = Cochrane Review 
* Studies were identified through online searches of databases including MEDLINE, 
PsychINFO, and Google Scholar, as well as searching citing articles for each meta-analysis.  
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In terms of outcome measures, while there was variation between meta-analyses in 
the outcomes that improved following psychological interventions, positive effects for 
reported pain, mood, quality of life, anxiety, depression and catastrophising have been 
reported with some consistency. 
The absence of large effects that are stable over time may be interpreted as a failing 
of psychological interventions to bring about considerable change for patients living with 
chronic pain. However, as Morley and Williams (2015) have cautioned, we must be careful 
not to hold overly optimistic expectations of psychological interventions for chronic pain. It 
is important to remember that those living with chronic pain have often been in pain for 
several years before seeking psychological support. Managing the distress that comes as a 
result of living in pain is inevitably difficult and complicated work. Representing the 
outcome of this complex work is, perhaps, oversimplified by the presentation of summary 
effect sizes.  
In summary, findings from the meta-analyses available converge to suggest that 
psychological interventions for a range of chronic pain diagnoses are effective. Effect sizes 
are small, but appear to be consistent across a range of outcome measures. However, despite 
certainty within the field that psychological treatments for chronic pain are effective 
(Eccleston, Morley, & Williams, 2013), many unanswered questions remain. For instance, 
while we can broadly say that psychological interventions are effective, we do not know 
whether there are particular treatment components that are important for outcome. It may be 
that all treatment components within each intervention are equally important in contributing 
to change. I will now discuss what we know about the content of the psychological 
interventions that are investigated in primary studies of chronic pain.   
 
1.3.2 Content of psychological interventions  
In this section, I will discuss the possibility that there is overlap in the treatment 
components used across psychological interventions that are assumed to be independent. I 
will propose that it is time for a detailed description of the content that makes up the 
psychological interventions that have investigated by primary studies of chronic pain.  
As described earlier, the meta-analyses conducted thus far usually focus on 
evaluating primary trials comparing a particular type of treatment package, such as ACT, 
and excluding trials that use alternative treatments. For example, Veehof et al. (2016) 
completed a meta-analysis comparing trials of ACT and mindfulness based stress reduction 
(MBSR). The implicit assumption here is that ACT and MBSR are sufficiently different to 
be considered independent of each other. However, this assumption may be flawed. To 
continue with the meta-analysis completed by Veehof et al. as an example, while there are 
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likely to be differences between ACT and MBSR, there will also be treatment components 
that overlap between them, such as bringing a non-judgemental approach to one’s thoughts. 
Although randomised controlled trials (RCTs) are designed to control for as much 
variability as possible, in-depth descriptions of treatment protocols are not always provided 
in publications. A potential implication of this is that even if two treatments in the same trial 
are sufficiently different, the same treatment packages in a different trial may be delivered 
according to different protocols. Adding strength to this argument, Morley and Williams 
(2015) highlighted that a definitive CBT protocol does not exist, and treatment programmes 
usually comprise of multiple components. Indeed, studies might state that they are 
investigating CBT but the intervention used may actually include multiple components that 
are not unique to this therapy, such as relaxation. This is important when synthesising data 
across trials because interventions may be given the same name but operationalised 
differently, or alternatively, may be given different names but operationalised similarly 
(Coe, 2002).  
To add to this complexity, there is reason to believe that interventions being used by 
clinicians are more heterogeneous than those being studied at a primary level through RCTs. 
For example, Fenton and Morley (2013) found that more pain management programmes 
(PMPs) completed as part of RCTs were classified as ‘CBT’ or ‘CBT in addition to other 
components’ than were PMPs completed by clinicians in routine clinical practice. PMPs 
were nearly twice as likely to be described as ‘mixed’ interventions by clinicians delivering 
interventions routinely. On the one hand, the use of a variety of psychological interventions 
for chronic pain may be advantageous. If we subscribe to a biopsychosocial model of 
chronic pain, then an intervention that includes several different components targeting 
different aspects of the model may well be beneficial. On the other hand, for this to be the 
case, we must be confident that all components of treatment are effective. Our approach to 
developing interventions for people with chronic pain cannot be an unconsidered ‘bolting 
on’ strategy, where the latest treatment is added to an existing protocol without an 
evaluation of the value it adds in relation to outcome. This potential for confounding of 
treatment effects due to their shared components, coupled with the finding that few meta-
analyses have established superiority of one active psychological intervention over another, 
suggests that we need to better describe the various components that comprise broad 
intervention labels. Developing more detailed knowledge about what components comprise 
each broad intervention may help us to understand the extent to which there is overlap in the 
treatments being delivered.  
When conceptualising treatment components, it is helpful to divide them into two 
groups: treatment content and treatment context. Treatment content refers to aspects of the 
treatment itself, for example, whether specific components of treatment such as behavioural 
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activation or mindfulness were included. Treatment context refers to the way in which the 
treatment components were delivered. For example, how much treatment was delivered, or 
how experienced the therapist was. In addition to treatment components, it may be prudent 
to also consider how aspects of participant characteristics could relate to magnitude of 
change. As an example of this, it may be that those who have lived with pain for more years 
are less likely to change because their difficulties are more established. Or perhaps those 
who are younger can more readily make use of the psychological interventions on offer? 
Although such participant characteristics are different to components relating to treatment 
content and context, it is important to consider that outcome may be influenced by factors 
other than those that the researcher can control.  
1.4 Understanding Treatment Components: Meta-Regression 
The need to better understand whether certain treatment components are more 
important than others in psychological interventions for chronic pain has been identified for 
some time (Morley & Williams, 2002). The same authors have more recently asserted that 
the challenge for the field is to discover ways of enhancing the overall magnitude of effects 
(Morley & Williams, 2015). It is possible that a better understanding of the treatment 
components included in broad treatment packages could enable clinicians to deliver greater 
improvement for patients. Meta-regression is one statistical approach that can be used to 
explore the relationship between components of treatment and outcome. In this section, I 
will describe how meta-regression analyses have been used in attempts to better understand 
treatment components.  
Meta-regression can be thought of as similar to simple regression. Simple 
regression enables us to fit a model to our data and use the model to predict outcome values 
from a predictor variable. In essence, regression enables us to predict an outcome variable 
from a predictor variable (Field, 2009). As an illustrative example, we might use regression 
to predict a depression score (an outcome value) from the number of social networks a 
person has (a predictor variable). Whereas simple regression deals with data from within a 
trial, meta-regression deals with data across multiple trials (Borenstein, Hedges, Higgins, & 
Rothstein, 2009). Despite the potential of meta-regression to aid our understanding of how 
interventions bring about change, it has rarely been used by clinical psychologists. For 
example, since its inception in 1981, the journal ‘Clinical Psychology Review’ has 
published just 26 reviews that use meta-regression to explore treatment effectiveness for 
adults with different types of mental health difficulties. In the field of psychological 
interventions for chronic pain, meta-regressions have been used with even less frequency. 
To my knowledge, there have been just two studies that have used meta-regression. The 
first, Hoffman et al. (2007), explored the impact of psychological interventions for chronic 
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low back pain. Their analyses considered the following predictors and their influence on 
effect size across 22 trials: percentage of males, sample size, study methodology elements 
(e.g. treatment credibility), and age. Interestingly, the authors also noted that there were 
three other predictors that they could not include due to insufficient data: duration of pain, 
ethnicity, and education. Hoffman and colleagues found that only the percentage of males 
and study methodology predicted outcome, in the direction of smaller effect sizes. The lack 
of substantive findings for moderator effects led the authors to conclude that treatment 
effects do not vary by patient and study. The second meta-regression was published by 
Glombiewski et al. (2010), and explored 23 studies of psychological interventions for 
fibromyalgia. Glombiewski and colleagues found moderating effects for all three 
moderators that they tested: study quality, treatment dose (total number of hours spent in 
psychological interventions), and treatment type (e.g. CBT, relaxation etc.). Reductions in 
pain intensity and depression were moderated by both treatment dose and study quality, 
with higher doses and lower quality being associated with larger effect sizes. The finding 
that lower quality is associated with larger effects may be surprising, but is perhaps 
explained by the possibility that studies with lower quality account for less error and might 
include more bias, which inflates estimates of effect. Functional status was moderated only 
by the quality of studies, and not by treatment dose. There were no significant moderators of 
catastrophising. ‘Type of treatment’ analyses revealed that CBT reduced scores of pain 
intensity significantly more than other psychological interventions. On the basis of their 
findings, the authors recommended that patients with fibromyalgia be offered high-dose 
CBT.  
 Taken together, these two meta-regressions present discrepant findings. There are 
differential findings between Hoffman et al. and Glombiewski et al. in terms of how 
treatment content  (e.g. dose), treatment context (e.g. study methodology) and participant 
characteristics (e.g. age, and gender) are related to outcome. It is surprising that there have 
not been further attempts to replicate this methodology to help clarify this incongruity. This 
is especially surprising given that potentially important factors, such as duration of pain, 
have not been investigated because of insufficient data. Indeed, it has long been 
recommended that meta-analysts attend more to between-study differences when using 
meta-analytic approaches (Wilson & Lipsey, 2001).  One reason for the paucity of meta-
regressions in the field may be the lack of primary studies needed to run such analyses well. 
This was the case for both Eccleston et al. (2009) and Williams et al. (2012), who reported 
that they had planned to run moderator analyses but were unable to because of small sample 
sizes. 
Despite the continuing surge in the number of RCTs of psychological interventions 
for chronic pain, the most recent comprehensive meta-analysis (exploring all psychological 
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interventions for all types of chronic pain) was conducted in 2012 (Williams et al.). This 
suggests there is a need to update this search, and capitalise on the increased number of 
RCTs by using meta-regression analyses to further delineate the effect of treatment 
components to help understand the discrepancy between the two meta-regressions described 
above.  
1.5 The Dose-Response Question  
Although there are many treatment components that would be interesting to 
investigate, in this section I will introduce ‘treatment dose’ as a component that merits more 
attention. Lending a concept from the field of pharmacology, one can think about this as the 
‘dose-response’ question (Howard, Kopta, Krause, & Orlinsky, 1986). I will analyse 
previous attempts to answer the dose-response question in the field of psychological 
interventions for chronic pain, and highlight why further investigation of the dose-response 
question is necessary.  
The dose of treatment is important for three reasons. Firstly, high dose interventions 
are more intensive for patients. With this comes an ethical imperative to ensure that high-
dose interventions are effective and that we are not ‘wasting time’ for patients. Secondly, 
high dose interventions are time consuming for clinicians. The longer a treatment takes for 
an individual patient – or group of patients – the fewer patients can be seen by the clinician. 
This means that the issue of dose is inter-related with the dilemma of seeing more patients 
for less time or fewer patients for longer. Finally, high dose interventions are financially 
costly. This is especially important at the moment; with more financial pressure on 
healthcare services around the world than ever before (Deloitte, 2017), there is an economic 
imperative to ensure that greater returns are seen in exchange for higher doses.  
In addition to the conclusion drawn by Glombiewski et al. (2010) that patients with 
fibromyalgia ought to be offered high dose CBT, other investigations of how much 
treatment might be needed for significant improvements in functioning have focused on low 
back pain. An early attempt to answer this question concluded that more than 100 hours of 
multi-disciplinary rehabilitation was required for significant improvements to be seen 
(Guzmán et al., 2001). However, there were significant limitations to this research. Only ten 
trials were included in the analysis, which focused only on selected outcome measures 
(excluding psychological and physical measures). Moreover, only trials of multi-
disciplinary treatments were included.  Perhaps most crucially, Guzmán and colleagues 
compared studies based on a dichotomy between those where dose was less than 30 hours, 
and those where dose was more than 100 hours. At best, we can say that this was a limited 
attempt to explore the dose-response question. Despite these shortcomings, the authors’ 
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conclusion that more than 100 hours of rehabilitation are required was incorporated into 
National Institute of Clinical and Health Excellence guidance (NICE, 2009). References to a 
minimum number of hours has been removed in the latest guidelines, with no updated 
recommendations about duration of treatment (NICE, 2016). 
More recently, Waterschoot et al. (2014) have attempted to account for some of 
these methodological issues. They conducted more complex and sophisticated analyses 
using a statistical approach called multilevel modelling to analyse outcomes from pain 
rehabilitation programmes for adults with low back pain. Based on this, they emphasized the 
complexity of the dose-response question and concluded that a wide range of contact hours 
(from 6.4 to 196.8 hours) could lead to greater effect sizes than control interventions. Key 
findings from the paper were that evaluation moment (i.e. immediately post-intervention, 6-
month follow-up etc.), number of disciplines, type of intervention, duration of intervention 
in weeks, percentage of women and age influenced the outcomes of pain rehabilitation 
programmes. It is interesting that duration of intervention in weeks and not dose of 
intervention in hours influenced outcome. Waterschoot and her colleagues concluded that 
the independent effect of dose variables could not be distinguished from content because 
these variables were strongly associated. Although this analysis of the dose-response 
question is laudable, it was limited in that it only included 18 studies, and was restricted to 
patients with low back pain. With this in mind, Waterschoot’s paper presents an interesting 
methodology, and a potential to apply this to a broader set of trials and outcome data.  
 In summary, attempts to explore the dose-response question have been limited and 
have highlighted the complexity of trying to tease apart other interrelated and important 
aspects of treatment that may also be important. Rather than such complexity preventing 
further analysis, I argue that we must further explore the issue of dose because of this 
complexity. As Williams (2014) points out, Waterschoot et al. have “laid some ground for 
larger and more incisive attempts to disentangle some of the factors in pain management 
that we can manipulate to improve treatment provision” (p. 9). The increased number of 
trials, and inclusion criteria that are broader than those used by Waterschoot et al. may mean 
that the relationship between treatment dose and outcome can be better explored.  
1.6 Present Thesis  
  In sum, we know that psychological treatments for chronic pain are effective. 
However, there may be overlap in the treatment content of interventions that have been 
delivered. This overlap has not been reviewed, but is important for the conclusions that we 
can draw from attempts to synthesise outcomes across different interventions. Furthermore, 
to continue to develop our interventions, a better understanding of treatment components is 
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required. One important component is ‘dose’ of treatment. Meta-regression presents a 
sophisticated approach to exploring relationships between potential moderators, such as 
dose, and magnitude of change following a treatment.  
The primary purpose of the present thesis is to further explore the dose-response 
question. I will replicate the most recent comprehensive meta-analysis that included all 
types of non-cancer chronic pain, excluding headache, and all types of psychological 
interventions (Williams et al., 2012). The rationale for excluding chronic headaches is that 
the psychological interventions aim to reduce the frequency, intensity and duration of the 
headache. This is different to the aim of interventions for other types of chronic pain; to 
rehabilitate individuals in-spite of ongoing chronic pain. Similarly, psychological 
interventions for individuals with pain from life-threatening diseases such as cancer are not 
focused on rehabilitation in the same way that chronic pain interventions are. For these 
reasons, the present study focuses on interventions for non-cancer chronic pain excluding 
headaches. I will, however, also extend this review by using meta-regression to analyse dose 
as a potential moderator of change. Given the paucity of meta-regressions analysing 
psychological interventions for chronic pain, this will enable me to generate hypotheses 
about the relationship between dose and effect. The secondary purpose of this thesis is to 
explore specific descriptions of treatments delivered in trials to facilitate an improved 
understanding of what components of psychological treatments are delivered; moving away 
from broad labels of treatment packages. Due to the lack of consistent and convergent 
findings in this area it is difficult to sensibly hypothesise about the relationship that will be 
found. As such, this thesis ought to be considered hypothesis generating in nature.  
To conclude, I will explore whether ‘all treatment components are created equal’ by 
asking two broad questions:  
1. Is dose related to outcome in psychological interventions for adults with chronic 
pain?  
2. What are the core components of treatment being delivered in psychological 
interventions for chronic pain, and how do they differ between types of 
intervention?  
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2 Method 
In this section, I will outline my approach to identifying appropriate trials, data 
extraction, and data analysis in line with the Preferred Reporting Items for Systematic 
reviews and Meta-Analyses (PRISMA; Liberati et al., 2009). I will present summary data 
alongside descriptions of method to allow for ease of reading. For example, the number of 
studies selected is presented alongside the description of study search strategies.  
2.1 Ethical Considerations 
This thesis analysed data that is publically available in published journal articles. As 
such, it did not require the approval of an ethics committee.  
2.2 Search Methods 
2.2.1  Criteria for considering studies for analysis 
The criteria used by the most recent Cochrane review of psychological interventions 
for chronic pain was replicated (Williams, Eccleston, & Morley, 2012). For studies to be 
included, they had to be randomised controlled trials of credible psychological interventions 
for chronic pain in adults (> 18 years and older). Chronic pain was defined as pain lasting 
longer than three months, and excluded headache or pain associated with a malignant cause 
such as cancer. Psychological interventions were deemed to be credible if they had definable 
psychotherapeutic content, based on an existing psychological model or framework, and 
delivered, trained or supervised by a psychologist. Trials where the primary aim was not the 
alleviation of chronic pain were excluded. For example, trials treating insomnia in 
participants with chronic pain. Trials that were delivered online were also excluded, on the 
basis that the treatment characteristics were different to interventions delivered in-person 
(see Buhrman et al., 2015 for a review of internet interventions for chronic pain). Any trial 
that had an arm where the sample size was less than 20 was excluded. No restrictions were 
placed around type of outcome measure. Only primary publications of studies were 
included; publications reporting secondary analyses were excluded.   
2.2.2 Search strategy 
In line with Williams et al. (2012), electronic searches were completed of the 
Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE and PsychINFO. The 
searches included studies published between 2012 and January 2016. Filters were used to 
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include only studies of humans, and adults (18 years and older). Searches were completed 
twice. The first was completed in August 2016, and the second was in January 2017 to 
ensure that any studies published in the previous five months were included. No additional 
papers that met the inclusion criteria were found during the second search. Full details of the 
search strategy, including MeSH terms are provided in Appendix A.  
2.2.3  Selection of studies 
Trials included in the Williams et al. (2012) review were automatically selected. In 
addition, the initial search of literature published since 2012 yielded a total of 1452 studies. 
I evaluated whether each study met the inclusion criteria by following three steps; firstly, 
reviewing all titles, secondly, reviewing abstracts, and finally reviewing full texts. To 
compensate for the possibility of human error in evaluating such a large data set, a final year 
undergraduate psychology student was trained in evaluating whether studies met inclusion 
criteria. The student independently completed a review of all titles, and a sample of 50 
abstracts (17% of total abstracts reviewed). This process revealed that no relevant papers 
were missed, and exclusion and inclusion rates were similar between evaluators. The student 
excluded more studies earlier than I did, suggesting that my approach was more 
conservative. I completed a review of all full texts. Any queries regarding whether a paper 
ought to be included were discussed in supervision. Figure 2.1 shows the flow of studies 
through the search process, which resulted in 65 trials being included. One study was a 
long-term follow-up of an existing study (Tavafian, Jamshidi, & Mohammad, 2014). New 
data were extracted from this paper, but all other study data were only extracted from the 
original paper (Tavafian, Jamshidi, & Mohammad, 2011) to ensure that data such as 
participant demographics were not accounted for twice.  
2.3 Assessing Quality and Risk of Bias 
The Yates Quality Rating Scale (Yates, Morley, Eccleston, & Williams, 2005) and 
the Cochrane Risk of Bias Tool (Higgins et al., 2011) were used to assess quality and risk of 
bias. Table 2.1 lists the items included in both measures. To ensure that I could use these 
tools accurately, I trained myself by independently assessing the quality and bias of nearly 
half (48%) of trials included in Williams et al. (2012). Intra class correlation (ICC) 
coefficients were .81 and .84 for quality and bias ratings respectively. Yates et al. (2005) 
reported a median ICC of .81, suggesting that this calibration exercise was successful.  
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Figure 2.1. PRISMA flow diagram of studies through search process. 
2.3.1 Yates Quality Rating Scale 
The Yates Quality Rating Scale (Yates et al., 2005) is a tool to assess the quality of 
treatment and study design. It was developed specifically to evaluate quality in 
psychological treatment studies of chronic pain. As this thesis explored in-depth 
descriptions of the treatments delivered, only the study design items of the measure were 
used. 
There are 20 items evaluating study design quality, for example, whether the 
intervention was manualised, whether inclusion criteria were met, and whether there was a 
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six-month follow-up. A total score of 26 is possible, with higher scores indicating better 
quality. It has been noted that use of quality rating scales to assess risk of bias is limited 
because they often assign weights in ways that are difficult to justify (Higgins et al., 2011). 
As such, the Cochrane Risk of Bias Tool was also used.  
2.3.2 Cochrane risk of bias tool 
In line with Cochrane recommendations, I used the ‘Cochrane Risk of Bias Tool’ 
(Higgins et al., 2011) to assess four types of bias in included studies: selection bias, 
detection bias, attrition bias, and reporting bias. Five items assess these four types of bias, 
and responses are presented as ‘high risk of bias’, ‘low risk of bias’, or ‘unclear’. 
Justification of rating is also noted.  
Table 2.1. Items from Yates Quality Rating Scale and Cochrane Risk of Bias Tool. 
Yates Quality Rating Scale Items 
1. Are the inclusion and exclusion criteria specified?  
2. Is there evidence that CONSORT guidelines for reporting attrition have been 
followed? 
3. Is there a good description of the sample in the trial?  
[Sub items: sample characteristics; group equivalence] 
4. Have adequate steps been taken to minimise biases?  
[Sub items: randomisation; allocation bias; measurement bias; treatment 
expectations] 
5. Are the outcomes that have been chosen justified, valid and reliable?  
6. Has there been a measure of any sustainable change between the treatment and 
control groups (i.e. follow-up of six months or longer)? 
7. Are the statistical analyses adequate for the trial?  
[Sub items: Power calculation; Sufficient sample size, Planned data analysis; 
Statistics reporting; Intention to treat analysis] 
8. Has a good, well-matched alternative treatment group been used?  
 Cochrane Risk of Bias Tool Items 
1. Was the allocation sequence adequately generated?  
2. Was allocation adequately concealed?  
3. Was knowledge of the allocated interventions adequately prevented during the 
study?  
4. Were incomplete outcome data adequately addressed?  
5. Are reports of the study free of suggestion of selective outcome reporting?  
2.3.3 Overview of bias and quality scores 
As recommended by Liberati et al. (2009), Table 2.2 displays all studies that were 
included in this thesis, along with data about trial design quality and risk of bias within each 
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study. Figure 2.2 presents the risk of bias data across all trials, showing the percentage of 
studies with low, high and unclear risk of bias in relation to each of the five items measured 
by the ‘Cochrane Risk of Bias Tool’. Figure 2.2 shows that there was a relatively low or 
unclear risk of bias when viewed across all studies. The exception to this was that the risk of 
detection bias was relatively high because outcome assessments were not typically blinded. 
Although one might minimise the potential impact of not blinding assessors when most 
measures are self-report, it is plausible that assessors who are aware of the condition that 
participants were randomised to may consciously or unconsciously influence outcome. For 
example, if an assessor expects greater improvement because they know that a participant 
has received the active treatment, they may be more encouraging and positively reinforcing 
in their interactions than if they do not expect that a participant will have changed because 
they have been on a waiting list. Only four studies were without any risk of bias (Leeuw et 
al., 2008; Monticone et al., 2013; Sharpe & Schrieber, 2012; Somers et al., 2012). One study 
scored high across all risk of bias items (Mishra, Gatchel, & Gardea, 2000). Scores of trial 
design quality have increased slightly since the 2012 Cochrane review from 15.8/26 to 
17.59/26. This means that the trend for increased trial quality with year of publication 
continues to be statistically significant (Spearman’s rho = 0.46, p < .01). 
2.3.4 Publication bias 
Publication bias describes the tendency for journals to publish statistically 
significant results (Rothstein, Sutton, & Borenstein, 2006). This has the potential to skew 
the results of meta-analysis because effect sizes would be larger than if non-significant trials 
had been published. I assessed publication bias by calculating fail-safe N in accordance with 
methods outlined by Rosenthal (1979). Fail-safe N is a frequently used computation that 
estimates how many additional non-significant studies would be needed to reduce the 
treatment effect found in meta-analysis to zero. If the number of additional studies required 
is large (e.g. more than 5,000) then we can be more confident that the effect size found in 
the meta-analysis is robust (Rosenthal, 1991).
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Table 2.2. Quality and risk of bias summary for each included study. 
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Altmaier 1992 11 - - - - + 
Amris 2014 19 + + ? ? + 
Basler 1997 12 - - - + + 
Bennell 2016 22 + + + ? + 
Bliokas 2007 15 + - - + + 
Broderick 2014 17 + ? + + + 
Cash 2015 16 + + - + - 
Castel 2013 18 + - + - - 
Castro 2012 13 - + - - + 
Chavooshi 2016 15 - - ? - + 
Cherkin 2016 23 + + + ? + 
Ehrenborg 2010 17 ? - - + + 
Ersek 2008 21 + + + + - 
Evers 2002 18 ? + - + + 
Falcao 2008 14 ? - + ? + 
Geraets 2005 20 + + + + + 
Glombiewski 2010b  17 + ? - ? + 
Greco 2004 20 + - + ? + 
Haldorsen 1998 10 + + ? - - 
Hammond 2001 15 - + + - + 
Heutink 2012 17 - - - - + 
Jensen 2001 20 ? + ? - + 
Jensen 1997 13 ? - + - - 
Kääpä 2006 20 + + - ? + 
Khan 2014 15 + - - + + 
Karlsson 2015 19 + + - + + 
Keefe 1990 18 ? - - + + 
Keefe 1996 17 - - - ? + 
Kemani 2015 22 + - - ? - 
Kerns 2014 23 + + + + - 
Kraaimaat 1995 14 - - - ? + 
Leeuw 2008 24 + + + + + 
Litt 2009 11 + - - - + 
Luciano 2014 22 + + + ? + 
Martín 2012 19 + - ? + + 
McCarberg 1999 9 ? - - ? + 
McCracken 2013 16 + - + + + 
Mishra 2000 12 - - - - - 
Monticone 2012 20 + + + - + 
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Monticone 2013 22 + + + + + 
Nicassio 1997 15 ? - - + + 
Nicholas 2013 20 + + + - + 
Nicholas 2014 20 + + - - + 
Poleshuck 2014 19 + ? - - + 
Puder 1988 10 - - - ? - 
Scheidt 2013 21 ? + - - + 
Schmidt 2011 23 + + + ? + 
Sharpe 2012 24 + + + + + 
Siemonsma 2013 19 + + - - + 
Sleptsova 2013 18 + + - - + 
Smeets 2008 23 + + + ? + 
Somers 2012 22 + + + + + 
Tavafian 2011 19 - + - - + 
Thieme 2003 11 - - - ? + 
Thorsell 2011 13 ? - - ? + 
Turner 2006 22 + + + ? + 
Turner 1988 15 - - - ? + 
Van Koulil 2010 15 - - - ? + 
Van Der Maas 2015 18 + + - - + 
Vlaeyen 1996 16 - - - + + 
Wetherell 2011 24 + + + ? + 
Williams 1996 15 ? - + + - 
Zangi 2012 19 + + + - + 
Zautra 2008 19 + - + ? + 
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Figure 2.2. Risk of bias graph presented as percentages across all included studies. 
 
2.4 Data Extraction 
I extracted four types of data from each trial; participant demographics, treatment 
context, treatment content and treatment outcomes. In this section, I provide an overview of the 
types of data extracted. I used Microsoft Excel (version 15.33) to extract the data from each 
study, adapting a data extraction book created for previous reviews (Eccleston, Palermo, 
Williams, Lewandowski, & Morley, 2009; Williams et al., 2012). If data were missing, it was 
scored as ‘not reported’, meaning that I did not estimate or assume any data.  
2.4.1  Trial conditions 
All data were extracted at the level of the trial condition (sometimes referred to as the 
‘trial arm’). I classified trial conditions as ‘active treatment’ to identify the intervention of 
primary interest in each trial. I classified conditions as ‘active control’ when control participants 
were offered a treatment of any kind that was not the same as the target active treatment. Some 
trials had more than one active control condition, these were recorded in order as; ‘active control 
1, active control 2’, and so forth. I will use the term ‘active conditions’ throughout this thesis, to 
refer to active treatment and active control conditions. I also extracted data about wait list 
control (WLC) and treatments as usual (TAU) conditions. TAU conditions differ from active 
control conditions because they do not usually receive a consistent, structured intervention and 
support can vary from regular consultations to access to care, if needed.   
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2.4.2  Participant demographics  
I extracted information about the participant characteristics that were most frequently 
reported in trials. I decided which characteristics were frequently reported by extracting all 
information from the first five trials and looking at the data that were commonly reported across 
all. While this meant that the data extracted was determined by the trial data that was available, 
it also meant that some important information, such as number of previous treatments for 
chronic pain, was not frequently reported and therefore not extracted. Participant demographics 
were extracted for each arm of the trial. For example, the average age of the control group was 
extracted as well as the average age of the intervention group (rather than extracting the average 
of the whole sample). I extracted information about the following aspects of participants:  
• Age. 
• Gender – percentage female. 
• Marital status – percentage married, single, widowed, or separated. 
• Ethnicity – percentage White, Black, Asian, or ‘other ethnicity’.  
• Education – percentage who completed some level of high school education, graduated 
from university, or completed a post graduate qualification.  
• Employment status – percentage employed, unemployed, receiving social benefits, or 
receiving disability pensions. Students were rarely reported as being included in trials, 
as such information on whether participants were currently studying was not included.  
• Primary chronic pain diagnosis, secondary chronic pain diagnosis and the percentage of 
participants with these diagnoses.  
• Pain duration – the mean length of time that someone had been living with pain, 
measured in years. Where this was reported in months, I divided by 12 to get an 
estimate in years.  
• Medication – percentage on any medication, opioids, Nonsteroidal Anti-inflammatories 
(NSAIDs), antidepressants and anticonvulsants.   
2.4.3 Treatment context 
Data about treatment context includes information about the design of the trial. I 
extracted information about key characteristics, including: 
• Type of service – categorised as hospital, community, or university.  
• Treatment setting – categorised as either residential or outpatient. 
• Country – categorised as the name of the country where the trial was completed.  
• Manualisation – categorised as whether use of a treatment manual was reported. 
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• Adherence to manualisation – verbatim description of manualisation adherence 
extracted, these descriptions were subsequently coded categorically as ‘yes’ or ‘no’.  
• Therapist training – categorised as Not Reported, Inexperienced, Experienced, or 
Advanced.  
• Number of multi-disciplinary team (MDT) members – count of MDT members 
described. 
• Professions included in the MDT – list of all MDT members described.  
• Treatment dose (hours) – total hours of treatment.  
• Treatment duration (weeks) – total number of weeks over which treatment was 
delivered.  
• Treatment format – categorised as group or individual. 
• Mean group size.  
• Group size range.  
2.4.4  Treatment content  
Analysing data from trials on the basis of broad intervention names like ‘CBT’ or 
‘ACT’ poses a problem because interventions may be given the same name but operationalised 
differently, or alternatively, may be given different names but operationalised similarly (Coe, 
2002).  To enable a better understanding of the interventions that were delivered, specific data 
about treatment content were extracted. ‘Treatment content’ refers to specific information about 
what was delivered in each intervention. Descriptions of interventions were extracted verbatim 
from the text, and varied in specificity. A total of 475 unique descriptions of treatment content 
were found from the first extraction of information. To enable meaningful analysis of this data, 
broader treatment categories were created. This process involved ‘coding’ the treatment content 
descriptions until broad categories were established that best represented the content 
descriptions. Figure 2.3 demonstrates this process with the example of how the final code of 
‘Behaviour Strategies’ was established. Treatment content that was uncommon was excluded. 
For example, biofeedback occurred fewer than 25 times across all trial arms and so was 
excluded. Thirteen treatment categories were found to best represent the treatment content (see 
below). All treatment categories, along with their definitions, were reviewed and agreed in 
supervision. Each arm of every study was then examined to assess whether it included any of 
the 13 treatment categories. Only components that were specifically described were rated as 
being included. This meant that I made no assumptions about what components may have been 
included in an intervention. For example, if an intervention was called ‘cognitive behaviour 
therapy’ one could assume that cognitive strategies (such as cognitive restructuring) would have 
been used, but unless the study specifically reported that this was the case, I recorded the 
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component as ‘not included’. This means that the treatment categories used are only as good as 
the descriptions in the trial, but this was necessary to ensure the replicability of my method.  
 
Figure 2.3. Example of coding process to identify treatment category labels. 
 
1. Attention management - Includes distraction techniques used to help patients manage 
their pain. For example - external focusing, counting backwards and guided imagery. 
 
2. Behaviour Strategies - Describes techniques used to increase physical functioning, by 
helping patients to reduce psychological barriers to completing day-to-day activities. 
For example - exposure, pacing and activity scheduling.  
 
3. Cognitive Strategies - Includes any technique that aims to change maladaptive thoughts 
or the impact of thoughts on patients’ lives, such as thought challenging, cognitive 
restructuring, and cognitive defusion. While the theory and application of these 
strategies differ, it was deemed appropriate to group them because they all aim to work 
at a cognitive level.  
 
4. Communication - Includes techniques that aim to improve interpersonal relationships. 
Such as; assertiveness training, effective communication, and relationship issues. It 
could be argued that relationship issues ought to be considered separately to general 
issues of communication. However, they were grouped together because both serve the 
aim of improving interpersonal relationships.  
 
Data Extraction
57 unique 
descriptions of 
‘Behavioural 
Strategies’ were 
extracted. 
Examples:
‘Time-contingent 
pacing’
‘Systematic 
exposure’
‘Engaging in 
pleasant activities’
Coding –
Round 1
10 categories were 
created from the 
original 57 
extracted. 
Examples: 
‘Pacing’ 
‘Exposure’
‘Activity 
Scheduling’
Coding –
Round 2
The label 
‘Behavioural 
Strategies’ was 
deemed to best 
summarise the ten 
categories 
identified in 
Round 1. 
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5. Psychoeducation - Describes education that had a psychological component, such as 
education about mindfulness, stress or relaxation. There were ten occurrences of 
education being mentioned without further information about the content of the 
education. These occurrences were classed as psychoeducation because this was the 
most common category of education and all studies were of psychological interventions 
and so it seemed sensible that it was likely to be psychoeducation.  
 
6. Non-Psychological Education - Describes education that did not have a psychological 
component, such as education about medication, assistive devices or exercise.  
 
7. Exercise - Includes any physical activity where the aim is to improve physical fitness. 
There were three main types of exercises: strengthening, stretching and aerobic 
exercise. It was common for trials to not report exactly which types of exercises were 
included. It is worth noting that although ‘Exercise’ and ‘Behaviour Strategies’ 
categories may both result in more day-to-day activities and increased fitness, their aims 
are rather different. The conceptualisation here is that exercise aims to improve fitness, 
and behaviour strategies aim to reduce psychological barriers to engaging in activity.  
 
8. Goal Setting - Captures the inclusion of a goal setting in the trials. 
 
9. Homework - Captures the inclusion of homework as part of the therapeutic tasks. 
Details of the homework tasks were frequently unreported.  
 
10. Mindfulness - Captures any treatment component that aimed to bring purposeful 
attention to the present moment or to one’s body, such as mindfulness, body awareness 
training, and proprioceptive exercises. Relaxation was not included here (see 
‘Relaxation’ category below). It may be argued that mindfulness is a sub-component of 
attention diversion. However, mindfulness has a focus on attention toward the ‘self’, 
which is perhaps the opposite of what one might try to achieve through attention 
diversion. As such, I defined it to be sufficiently different to be worth a separate 
category. 
 
11. Problem Solving - Captures the inclusion of problem solving. Details of the strategies 
used as part of the problem solving component were seldom reported.  
 
12. Relapse Prevention - Reflects the planning at the end of treatment that aims to maintain 
positive change.  
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13. Relaxation - Describes strategies that aim to help patients relax. Such as; applied 
relaxation, breathing exercises, and progressive muscle relaxation. It may be argued that 
there is overlap between relaxation and mindfulness as categories (e.g. both often 
facilitate a focus on one’s breathing). However, the essence of mindfulness is to notice 
rather than to change, whereas relaxation exercises often encourage patients to change 
their breathing or muscle tension. Thus, differentiating mindfulness and relaxation was 
appropriate.  
2.4.5  Outcome measures and outcome domains 
The wide range of the measures used to evaluate trials has been well noted in the field 
of psychological interventions for chronic pain (Deckert et al., 2016; Fenton & Morley, 2013; 
Turk et al., 2003), and was a further challenge to data extraction. In total, data were available 
from 348 different measures. One way to manage this diversity is to use broader outcome 
domains that aggregate scores across different measures of the same construct. In accordance 
with Fenton and Morley's (2013) Delphi study, which established outcome domains in chronic 
pain trials, five outcome domains were used: pain experience, pain behaviour, emotional 
functioning, physical functioning and coping and cognitive appraisal. Importantly, this approach 
to analysis was different to the approach used in the Williams et al. (2012) Cochrane review, 
where a primary outcome measure was selected and used in the analysis across four domains 
(disability, pain, mood, and catastrophising). While there was an argument to be made for 
keeping analysis in line with Williams et al. (2012), namely that a more direct comparison 
between findings could be made, aggregating across multiple measures provided a more 
sophisticated approach to analysis because it enabled more data to be used. For example, while 
not all studies used a measure of catastrophising, many did use some measure of coping and 
cognitive appraisal (which includes measures of catastrophising). This meant that more data 
included in the primary trials could be included in my analyses.  
Table 2.3 provides a brief description of each domain, along with examples of 
questionnaires, and the number of studies included in this thesis that measured each domain. 
Pain experience and physical functioning were used in almost all studies (61 and 60 
respectively). Measures of pain behaviour were the least frequently used, with only 15 studies 
reporting data on pain behaviour. Purely biological measures were excluded, for example, blood 
samples to measure osteoarthritis.  
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Table 2.3. Overview and example measures of outcome domains. 
Outcome 
Domain 
Name 
Number 
of studies 
measuring 
domain 
Definition Example Measures 
Coping and 
Cognitive 
Appraisal 
39 Measures that aim to explore the 
degree to which participants are 
able to cope with aspects of living 
with chronic pain. It also includes 
measures that explore helpful and 
maladaptive cognitions related to 
chronic pain. 
 
Chronic Pain Acceptance 
Questionnaire (McCracken, 
Vowles, & Eccleston, 2004) 
Coping Strategies 
Questionnaire (Gil, 
Williams, Thompson, & 
Kinney, 1991) 
Emotional 
Functioning 
54 Measures participants’ mood, 
emotions, or anxiety.   
Beck Depression Inventory 
(Beck, Ward, Mendelson, 
Mock, & Erbaugh, 1961) 
Hospital Anxiety and 
Depression Scale (Zigmond 
& Snaith, 1983) 
 
Pain 
Behaviour  
15 Measures that capture overt 
expressions of pain, and 
behaviours that indirectly indicate 
expressions of pain such as visits 
to one’s General Practitioner, or 
taking pain medications. 
 
Pain Behaviour Checklist 
(Philips & Hunter, 1981) 
Number of Days in Hospital 
Pain 
Experience 
61 Measures that assess the aspects of 
pain itself, such as intensity or 
pain severity.  
Graded Chronic Pain Scale 
(Von Korff, Ormel, Keefe, 
& Dworkin, 1992) 
Visual Analogue Scale of 
Pain Intensity 
 
Physical 
Functioning 
60 Measures day-to-day disability 
caused by pain, such as quality of 
life, sleep and activities of daily 
living.  
Fibromyalgia Impact 
Questionnaire (Burckhardt, 
Clark, & Bennett, 1991) 
The West Haven-Yale 
Multidimensional Pain 
Inventory (Kerns, Turk, & 
Rudy, 1985) 
 
2.4.6  Outcome data  
Studies usually included continuous outcome data. Dichotomous outcome data were 
uncommon and were not extracted. A small number of trials reported percentages as outcome 
data. For example, the percentage of participants scoring within the clinical range for 
depression, however; such data were excluded because they were uncommon. Means and 
standard deviations (SDs) were extracted for all questionnaires presented in the trials. If means 
and SDs were not available, authors were contacted to request these data. Five authors 
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responded to my request and sent relevant data. If authors did not reply to my initial request one 
further prompt message was sent, thereafter the paper was excluded if no response was 
provided. This was the case for three studies. One author did reply to my request, but stated that 
the data requested (number of participants in each arm of the RCT) were not available and this 
paper was excluded.  
Five studies reported confidence intervals (CIs) instead of SDs. Equation 1 and 
Equation 2 were used to calculated SDs, where SEM is the standard error of the mean, HiCI 
and LoCI refer to the upper and lower confidence intervals respectively:  
Equation 1 	EFG = HIJKLMNJK	O.PQ  
Equation 2 	ER = EFG( S) 
Raw means and SDs were pooled together in three studies; (1) Jensen, Bergström, 
Ljungquist, Bodin, and Nygren (2001) reported data by gender, (2) Zautra et al. (2008) reported 
data by whether patients had a history of depression, (3) van Koulil et al. (2010), reported two 
active treatment conditions of primary interest. In all three cases, one group was created by 
using Equation 3 to calculate a pooled mean estimate (PooledM) and Equation 4 to calculate a 
pooled SD estimate (PooledSD).  
Equation 3 TNNUVWG = 	 GX	SX Y(GQ	SQ)SXY	SQ  
Equation 4 TNNUVWER = 	 ERXQ(SXLX) Y	 ERQQ(SQLX)SXY	SQ LQ 	
2.4.7  Follow-up data  
One challenge to extracting data was the variability of follow-up times used within 
trials. While most follow-up times were 6 or 12 months, there were occasions where follow-up 
times were atypical, such as two months post-intervention. If a trial had a follow-up time point 
that was atypical it was rounded to one of the following time-points: post intervention, 3, 6, 9, 
12, 18, and 24 months. Table 2.4 shows the number of trials included in this thesis that 
collected data at each time point. Nearly all trials collected data immediately following the 
intervention (n = 57). The next most frequently used follow-up time points were at 6 and 12 
months (included in 36 and 24 studies respectively).  
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Table 2.4. Number of studies collecting data at each time point. 
Follow-up 
time point 
Number 
of studies  
Post 57 
3 14 
6 36 
9 2 
12 24 
18 3 
24 1 
2.5 Data Analysis  
Data were analysed in two ways. Firstly, data regarding treatment content, context and 
participant characteristics were analysed using descriptive statistics. Next, meta-regression 
analyses were conducted to explore the quantitative outcome data. In this section, I outline the 
steps taken to complete the meta-regression analyses.  
A weighted meta-regression was used to examine the impact of predictors, such as dose, 
on outcome which was effect size between the active treatment condition and control conditions. 
This statistical approach has been recommended by The Cochrane Collaboration when looking 
at the relationship between clinical characteristics, such as dose of treatment, and intervention 
effect (Higgins & Green, 2011; p. 277). Analyses were conducted with data immediately 
following the intervention, when most trials reported data. In an attempt to deal with 
heterogeneity, a random-effects model was used as opposed to a fixed-effect model. The fixed-
effect model accounts for only within study variance, whereas the random-effects model is more 
conservative as it accounts for both within study variance and between study variance. This was 
important because the inclusion criteria were broad, and so it was probable that there would be 
significant heterogeneity between trials. A random-effects model has been recommended when 
this is believed to be the case (Thompson & Higgins, 2002). Moreover, a restricted maximum 
likelihood (REML) estimate was used because this accounts for the degrees of freedom 
employed in the model and so minimises the risk that the variances will be underestimated 
(Thompson & Higgins, 2002; Thompson & Sharp, 1999).  
There are no definitive standards for what the minimal number of studies needed to 
complete a meta-regression should be. However, ten has been recommended (Borenstein et al., 
2009). This suggests that the 64 trials included in this thesis justifies the use of a meta-
regression to explore relationships between treatment characteristics and outcome. As I aimed to 
generate hypotheses, the statistical convention of using a 0.05 level of significance was relaxed 
to 0.2. Such an adjustment is sensible when making multiple comparisons between explanatory 
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variables and outcome. Once all data were extracted into the Excel file, it was exported to SPSS 
(Version 22.0) for descriptive analysis. Meta-regression was conducted in Stata (Version 13.1), 
using the ‘metareg’ command (Harbord & Higgins, 2008).  
2.5.1  Calculating effect sizes 
As with meta-analysis, meta-regression involves the comparison of effect sizes. For the 
purposes of this thesis, I generated an effect size (ES) for the difference between the treatment 
condition and the active control condition, as well as the difference between the treatment and 
the TAU / WLC condition depending on which type of control group was used in the study. 
Grouping TAU and WLC conditions is not optimal because participants allocated to TAU do 
receive some treatment. However, the unstructured (and often unreported) nature of TAU 
conditions meant that the most conservative approach was to group it with WLC and compare 
both with the active treatment. This approach is in line with the Williams et al. (2012) review.  
A standardised mean difference (SMD) effect size was chosen (Hedges’ g) because the 
trials included here measure the same outcome domains (e.g. pain experience) but do so on 
different scales. The standardised mean difference (that is, standardised difference between 
means), allows us to standardise the results of studies into a uniform scale so that they can be 
meaningfully combined (Higgins & Green, 2011, p. 256). In calculating the SMD, a study’s 
effect size is calculated relative to the inverse variability observed in the study and between 
studies. To do this, an uncorrected effect size (Cohen’s d) was calculated for each outcome 
measure (Cohen, 1988). Equation 5 shows this formula, where MT refers to the mean of the 
active treatment, MC refers to the mean of the control condition, and SDPooled refers to the pooled 
standard deviation for both treatment and control conditions, which is a commonly used 
denominator when calculating d (Rosnow & Rosenthal, 1996).  
Equation 5  W = (GZL	GJ)ERTNNUVW  
SDPooled was calculated using Equation 6. Here, NT refers to the sample size of the 
treatment group, NC refers to the sample size of the control group, SDT refers to the SD of the 
treatment group, and SDC refers to the SD of the control group. These were all taken at the post 
treatment time point.  
Equation 6 ERTNNUVW = (([ZLX)ERZQ)Y(([JLX)ERJQ)[ZY[J LQ  
The Hedges correction for small sample bias was then added to account for the tendency 
of Cohen’s d to be upwardly biased when based on small samples (Hedges, 1981). Three steps 
were taken to achieve this: 
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1. Degrees of freedom (df) were calculated using Equation 7.   
2. The size corrected ES (\]) was then calculated using Equation 8.  
3. Hedges’^	was then calculated by multiplying the Cohen’s \ by the sample size adjusted 
Cohen’s \], as shown in Equation 9. 
Equation 7 W_ = 	 ([Z +	[J) − Q 
Equation 8 WI = X − Oa(W_)LX 
Equation 9 HVWbVcdb = (W)(WI) 
The final correction made to the ES was to correct for direction of change such that a 
positive ^ indicated improvement, and a negative ^ indicated deterioration. This was achieved 
by multiplying the ^ by -1 or 1 depending on the direction of pre-post change needed for 
improvement and whether the Hedges’ g was negative of positive before sign correction. The 
standard error of Hedges’ g was calculated using Equation 10.  
Equation 10 cV = 	 X[Z + X[J + 		 b XL(W_LQ)WIQ	(W_)  
Next, it was necessary to weight the effect sizes. This is important because studies vary 
in size, and those with a larger sample size often have a more precise estimate of the population 
effect size. As such, studies with larger sample sizes should carry greater weight than those with 
smaller samples. The recommended approach to weighting studies is by the inverse of their 
variance. This approach was used in line with Wilson and Lipsey's (2001) recommendations. As 
a random effects model was being used, the weights applied to each effect size needed to 
account for both within trial variance, and between trial variance. Equation 11 calculated 
weighted effect sizes accounting for both variances. Where eI refers to the weight of the effect 
size, cVIQ refers to the square of the standard error of the effect size and fg refers to the between trial 
variance.  
Equation 11  eI = XcVIQY	fg	 
Five trials compared an active treatment condition with two active control groups. For 
the purposes of these analyses only one active control arm was used for these trials. Moreover, 
meta-regression analyses were only conducted on data immediately following the intervention 
(‘post intervention’).  
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2.5.2  Assessing heterogeneity  
Heterogeneity was assessed using the two common statistics; τiand I2. The first, τi, is 
an estimate of the variance among true effect sizes. The second, I2, can be thought of as the 
percentage of overall heterogeneity that is due to variation of the true effects rather than chance 
(Higgins, Thompson, Deeks, & Altman, 2003). Higgins and his colleagues suggested that I2 
values of 25%, 50%, and 75% should be regarded as low, moderate and high heterogeneity, 
respectively (2003).  
2.5.3  Data cleaning  
All data were examined in the process of sign correction, which provided an opportunity 
to second check all data entry for human error. Data were also checked by highlighting all ESs 
above 1.5, to ensure that such a large score was not due to error in the data extraction process 
such as a decimal point in the wrong place. Finally, I compared the effect sizes calculated in this 
thesis with those presented in the appendices of Williams et al. (2012). This allowed me to 
explore whether my calculations were likely to be correct, and whether my adjustments for 
direction of change had been effective (i.e. that a positive effect size reflected a more effective 
active treatment condition). I did not find any exceptions that led me to believe that there had 
been any errors in my calculations. This process was particularly useful for confirming that 
large effect sizes were not due to error in the statistical method employed here. For example, I 
calculated the effect size for pain experience from Thieme et al. (2003) to be 1.56. This is 
similar to the calculation of 1.64 by Williams et al. (2012). It is important to note that we would 
not expect this number to be identical because I aggregated across multiple measures to 
calculate effect sizes, whereas Williams and colleagues identified the primary outcome measure 
to calculate effect sizes.  
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3 Results 
My results are presented in three sections. Firstly, a detailed analysis of the included 
studies, their participants and the treatments delivered. Secondly, a description of the meta-
analytic results without accounting for predictors. Finally, I will present the results of my meta-
regression analyses.  
3.1 Characteristics of Included Studies 
3.1.1 Overview 
Key study characteristics are presented in Table 3.1. The 64 included studies were 
published between 1988 and 2016. Studies were conducted across 15 different countries, but 
most were conducted in the United States (n = 20), the Netherlands (n = 11), or Sweden (n = 6). 
The type of service where the treatment was delivered was reported in 51 studies. Of these, 24 
were conducted in hospitals, 14 were community based, and 13 were in a university setting. 
Residential interventions were uncommon; with only four trials (Altmaier et al., 1992; Jensen et 
al., 1997; Thieme et al., 2003; Williams et al., 1996), the remainder investigated outpatient 
interventions.  
3.1.2 Therapist characteristics 
I recorded therapist experience as either (i) ‘inexperienced’, defined as minimal training 
and experience, (ii) ‘experienced’, defined as between 1-5 years of experience or a description 
of comprehensive training provided, and (iii) ‘advanced’, defined as more than five years of 
experience, and extensive training. A total of 29% of conditions had no description of therapist 
experience and could not be classified. Of those that did describe therapist experience, 43% 
were delivered by experienced therapists, 15% were delivered by inexperienced therapists, and 
only 12% delivered by therapists with advanced experience. I recognise that these classifications 
are a crude measure of therapist experience, however, detailed descriptions of therapist 
experience were rarely reported. These broad classifications enabled me to gain at least a 
general sense of therapist experience.  
Multidisciplinary team (MDT) interventions were relatively common, accounting for 
nearly half of active treatment and control conditions (48%), the remaining conditions were 
delivered by one professional (52%). Of the interventions delivered by a MDT, the mean 
number of professionals in each team was 3 (SD = 1, Range = 2-6). Psychologists delivered 
most active treatment and control interventions (74%). Although this number may seem high, it 
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means that a quarter of interventions were delivered by non-psychologists. Physiotherapists 
frequently delivered interventions (47%), with medical physicians, nurses and occupational 
therapists delivering 31%, 22%, and 16% of interventions respectively.  
3.2 Participant Characteristics  
3.2.1 Number of participants  
A total of 7,840 participants were included at baseline, with data provided from 6,433 
immediately post-treatment. A total number of 3,557 participants were randomised to receive 
the active treatment. The mean number of participants per trial had reduced from 114 in 
Williams et al. (2012), to 99 here. Although this is still an increase from the review by Eccleston 
et al. (2009), which reported a mean of 91 participants per trial. 
3.2.2 Attrition  
 Average attrition rates were relatively low between baseline and immediately following 
intervention. Across all participants and study conditions the attrition rate was 16%. This was 
slightly higher for active control conditions than active treatment conditions (21% compared 
with 19%). The lowest attrition rate was for TAU / WLC conditions (7%). These attrition rates 
are comparable to other meta-analysis of chronic pain, such as Glombiewski et al., (2010) who 
reported 21% and 20% for  treatment and control group, respectively. More recently, Sielski, 
Rief, and Glombiewski (2017) reported 17% for both treatment and control groups.  
3.2.3 Participant demographics 
Demographic data were similar to those presented in the 2012 review. Women usually 
outnumbered men, with the mean percentage of women per trial being 74% (SD = 21, Range = 
6-100%). Twelve studies included only women. The mean age of participants was 50 (SD = 9). 
The range of mean ages varied widely between studies (Range = 34-82). Most participants were 
educated to high school level (including college diplomas; 67%), over a quarter had an 
undergraduate degree (26%), and few held post graduate qualifications (14%). It is not possible 
to describe participants’ ethnicity as only seven trials reported data on ethnicity.  
3.2.4 Pain characteristics 
Participants had been living with pain for a median of 9 years (Range = 1-35, based on 
34 studies providing data). Most studies investigated specific types of pain (47 out of 64 trials), 
for example; only recruiting participants with a diagnosis of fibromyalgia or chronic low back 
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pain. As such, 100% of participants in those studies had the same type of chronic pain diagnosis. 
The most frequently reported type of pain was fibromyalgia (24% of participants), followed by 
arthritis and low back pain (24% and 21% respectively). The remaining participants had a 
variety of less commonly investigated chronic pain diagnoses, such as pain of the legs and feet, 
lupus, and temporomandibular joint disorder. Table 3.2 summarises key participant 
demographic information.  
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Table 3.1. Study characteristics of included trials. 
First Author & 
Date 
Country Primary Type of 
Pain 
Trial Arm Type of Treatment Intervention 
Format 
 
Dose 
(hours) 
Duration 
(weeks) 
Altmaier 1992 United 
States 
Low Back Pain Active Treatment Multidisciplinary Group Group NR 3 
Treatment as Usual Multidisciplinary Group 
 
Group NR 3 
Amris 2014 Denmark Fibromyalgia Active Treatment Multidisciplinary Group Group 35 2 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 2 
Basler 1997 Germany Low Back Pain Active Treatment Cognitive Behavioural Therapy Group 24 12 
Control Treatment 1 Medication / Medical Visits 
 
Individual NR NR 
Bennell 2016 Australia Knee Osteoarthritis Active Treatment Coping Skills Individual 11.66 12 
Control Treatment 1 Coping Skills Individual 7.5 12 
Control Treatment 2 Physiotherapy / Exercise 
 
Individual 4.1 12 
Bliokas 2007 Australia Low Back Pain Active Treatment Multidisciplinary Group Group 66.5 8 
Control Treatment 1 Multidisciplinary Group Group 66.5 8 
Waiting List No Treatment - Control Group 
 
N/A - Control NR NR 
Broderick 2014 United 
States 
Osteoarthritis Active Treatment Coping Skills Individual 6.25 0 
Treatment as Usual Unknown – TAU 
 
NR 0 10 
Cash 2015 United 
States 
Fibromyalgia Active Treatment Mindfulness Programme Group 20 8 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Castel 2013 Spain Fibromyalgia Active Treatment Multidisciplinary Group Group 48 12 
Treatment as Usual Medication / Medical Visits Individual 0 12 
Castro 2012 Brazil Musculoskeletal 
Pain 
Active Treatment Cognitive Behavioural Therapy Group 20 10 
Treatment as Usual Unknown – TAU 
 
NR NR NR 
Chavooshi 2016 Iran Medically 
Unexplained Pain 
Active Treatment Other Individual 20 20 
Control Treatment 1 Mindfulness Programme Group 12 8 
Treatment as Usual Unknown – TAU 
 
NR 0 0 
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First Author & 
Date 
Country Primary Type of 
Pain 
 
Trial Arm Type of Treatment Intervention 
Format 
Dose 
(hours) 
Duration 
(weeks) 
Cherkin 2016 United 
States 
Low Back Pain Active Treatment Mindfulness Programme Group 22 8 
Control Treatment 1 Cognitive Behavioural Therapy Group 16 8 
Treatment as Usual Unknown – TAU 
 
NR 0 0 
Ehrenborg 2010 Sweden Neck and Shoulder 
Pain 
Active Treatment Multidisciplinary Group Group 150 6 
Control Treatment 1 Multidisciplinary Group 
 
Group 150 6 
Ersek 2008 United 
States 
Legs / Feet Active Treatment Other Group 10.5 7 
Control Treatment 1 Education 
 
Individual 0 7 
Evers 2002 Netherlands Rheumatoid 
Arthritis 
Active Treatment Cognitive Behavioural Therapy Individual 11 24 
Treatment as Usual Unknown – TAU 
 
NR NR NR 
Falcao 2008 Brazil Fibromyalgia Active Treatment Cognitive Behavioural Therapy Group 30 10 
Control Treatment 1 Medication / Medical Visits 
 
Individual NR 10 
Geraets 2005 Netherlands Shoulder Pain Active Treatment Behavioural Intervention Group 18 12 
Treatment as Usual Unknown – TAU 
 
NR NR NR 
Glombiewski 
2010b 
Germany Back Pain Active Treatment Cognitive Behavioural Therapy Individual 25 25 
Control Treatment 1 Cognitive Behavioural Therapy Individual 25 25 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 NR 
Greco 2005 United 
States 
Lupus Active Treatment Cognitive Behavioural Therapy Individual 6 6 
Control Treatment 1 Other Individual 6 6 
Treatment as Usual Medication / Medical Visits 
 
Individual 0 0 
Haldorsen 1998 Norway Back Pain Active Treatment Cognitive Behavioural Therapy Group 120 4 
Treatment as Usual Unknown – TAU 
 
NR 0 0 
Hammond 2001 United 
Kingdom 
Rheumatoid 
Arthritis 
Active Treatment Cognitive Behavioural Therapy Group 8 4 
Control Treatment 1 Education 
 
Group 8 4 
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First Author & 
Date 
Country Primary Type of 
Pain 
Trial Arm Type of Treatment Intervention 
Format 
 
Dose 
(hours) 
Duration 
(weeks) 
Heutink 2012 Netherlands Spinal Cord Injury Active Treatment Multidisciplinary Group Group 30 10 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Jensen 2001 Sweden Back Pain Active Treatment Multidisciplinary Group Group 136 4 
Control Treatment 1 Cognitive Behavioural Therapy Group 56 4 
Control Treatment 2 Physiotherapy /  Exercise Group 80 4 
Control Treatment 3 Unknown – TAU 
 
NR 0 0 
Jensen 1997 Sweden Back Pain Active Treatment Multidisciplinary Group Group 200 5 
Control Treatment 1 Multidisciplinary Group 
 
Group 200 5 
Kaapa 2006 Finland Low Back Pain Active Treatment Multidisciplinary Group Group 70 8 
Control Treatment 1 Physiotherapy  / Exercise 
 
Individual 10 8 
Khan 2014 Pakistan Low Back Pain Active Treatment Multidisciplinary Group Group 36 12 
Control Treatment 1 Physiotherapy / Exercise 
 
Group 36 12 
Karlsson 2015 Sweden Fibromyalgia Active Treatment Cognitive Behavioural Therapy Group 69 24 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Keefe 1990 United 
States 
Knee Osteoarthritis Active Treatment Coping Skills Group 15 10 
Control Treatment 1 Education Group 15 10 
Treatment as Usual Unknown – TAU 
 
NR 0 0 
Keefe 1996 United 
States 
Knee Osteoarthritis Active Treatment Coping Skills Group 20 10 
Control Treatment 1 Coping Skills Group 20 10 
Control Treatment 2 Education 
 
Group 20 10 
Kemani 2015 Sweden Idiopathic Pain Active Treatment Acceptance and Commitment Therapy Group 18 12 
Control Treatment 1 Relaxation 
 
Group 18 12 
Kerns 2014 United 
States 
Low Back Pain Active Treatment Cognitive Behavioural Therapy Individual 10 10 
Control Treatment 1 Cognitive Behavioural Therapy Individual 10 10 
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First Author & 
Date 
Country Primary Type of 
Pain 
Trial Arm Type of Treatment Intervention 
Format 
 
Dose 
(hours) 
Duration 
(weeks) 
Kraaimaat 1996 Netherlands Rheumatoid 
Arthritis 
Active Treatment Cognitive Behavioural Therapy Group 20 10 
Control Treatment 1 Other 
 
Group 20 10 
Leeuw 2008 Netherlands Low Back Pain Active Treatment Behavioural Intervention Group 16 8 
Control Treatment 1 Behavioural Intervention 
 
Group 26 13 
Litt 2009 United 
States 
Temporomandibula
r Joint Disorder 
Active Treatment Cognitive Behavioural Therapy Group NR 6 
Treatment as Usual Other 
 
Group NR 6 
Luciano 2014 Spain Fibromyalgia Active Treatment Acceptance and Commitment Therapy Group 20 NR 
Control Treatment 1 Medication / Medical Visits Individual 0 0 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Martin 2012 Spain Fibromyalgia Active Treatment Multidisciplinary Group Group 21 6 
Control Treatment 1 Medication / Medical Visits 
 
Individual 0 0 
McCarberg 1999 United 
States 
Low Back Pain Active Treatment Cognitive Behavioural Therapy Group 16 8 
Control Treatment 1 Other 
 
NR 0 0 
McCracken 2013 United 
Kingdom 
Fibromyalgia Active Treatment Acceptance and Commitment Therapy Group 16 2 
Treatment as Usual Unknown – TAU 
 
NR 0 0 
Mishra 2000 United 
States 
Temporomandibula
r Joint Disorder 
Active Treatment Cognitive Behavioural Therapy Group 24 8 
Control Treatment 1 Cognitive Behavioural Therapy Group 18 8 
Control Treatment 2 Other 
 
Group 18 8 
Waiting List No Treatment - Control Group N/A - Control 0 0 
Monticone 2012 Italy Neck Pain Active Treatment Multidisciplinary Group Individual 10 12 
Control Treatment 1 Physiotherapy / Exercise 
 
Individual 10 12 
Monticone 2013 Italy Low Back Pain Active Treatment Multidisciplinary Group Individual 17 57 
Control Treatment 1 Physiotherapy / Exercise Individual 10 57 
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First Author & 
Date 
Country Primary Type of 
Pain 
Trial Arm Type of Treatment Intervention 
Format 
 
Dose 
(hours) 
Duration 
(weeks) 
Nicassio 1997 United 
States 
Fibromyalgia Active Treatment Behavioural Intervention Group 15 10 
Control Treatment 1 Education 
 
Group 15 10 
Nicholas 2013 Australia Multiple Sites Active Treatment Multidisciplinary Group Group 16 4 
Control Treatment 1 Other Group 16 4 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Nicholas 2014 Australia Multiple Sites Active Treatment Cognitive Behavioural Therapy Group 120 5 
Control Treatment 1 Cognitive Behavioural Therapy 
 
Group 120 5 
Poleshuck 2014 United 
States 
Pelvic Pain Active Treatment Other Individual 8 36 
Control Treatment 1 Other 
 
Individual 0 36 
Puder 1988 United 
States 
Musculoskeletal 
Pain 
Active Treatment Cognitive Behavioural Therapy Group 20 10 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Scheidt 2013 Germany Fibromyalgia Active Treatment Other Individual 25 25 
Treatment as Usual Unknown – TAU 
 
Individual 1 24 
Schmidt 2011 Netherlands Fibromyalgia Active Treatment Mindfulness Programme Group 27 8 
Control Treatment 1 Other Group 20 8 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Sharpe 2012 Australia Rheumatoid 
Arthritis 
Active Treatment Cognitive Behavioural Therapy Individual 8 8 
Control Treatment 1 Other Individual 8 8 
Control Treatment 2 Behavioural Intervention Individual 8 8 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Siemonsma 2013 Netherlands Low Back Pain Active Treatment Cognitive Behavioural Therapy Group 14 14 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Sleptsova 2013 Switzerland Medically 
Unexplained Pain 
Active Treatment Cognitive Behavioural Therapy Group 37.5 24 
Control Treatment 1 Physiotherapy / Exercise  Group 37.5 24 
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First Author & 
Date 
Country Primary Type of 
Pain 
Trial Arm Type of Treatment Intervention 
Format 
 
Dose 
(hours) 
Duration 
(weeks) 
Smeets 2006 Netherlands Low Back Pain Active Treatment Multidisciplinary Group Group 78 10 
Control Treatment 2 Physiotherapy / Exercise Group 52.5 10 
Control Treatment 1 Behavioural Intervention 
 
Group 23.5 10 
Somers 2012 United 
States 
Osteoarthritis Active Treatment Coping Skills Group 40.5 24 
Control Treatment 1 Coping Skills Group 18 24 
Control Treatment 2 Other Group 22.5 24 
Treatment as Usual Unknown – TAU 
 
NR NR NR 
Tavafian 2011 Iran Low Back Pain Active Treatment Multidisciplinary Group Group 10 24 
Control Treatment 1 Medication / Medical Visits 
 
Individual NR NR 
Thieme 2003 Germany Fibromyalgia Active Treatment Behavioural Intervention Group 75 5 
Control Treatment 1 Physiotherapy / Exercise 
 
Group 75 5 
Thorsell 2011 Sweden NR Active Treatment Acceptance and Commitment Therapy Individual 6.5 7 
Control Treatment 1 Relaxation 
 
Individual 6.5 7 
Turner 2006 United 
States 
Temporomandibula
r Joint Disorder 
Active Treatment Cognitive Behavioural Therapy Individual NR 8 
Control Treatment 1 Other 
 
Individual NR 8 
Turner 1988 United 
States 
Low Back Pain Active Treatment Cognitive Behavioural Therapy Group 16 8 
Control Treatment 1 Behavioural Intervention Group 16 8 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Van Koulil 2010 Netherlands Fibromyalgia Active Treatment Cognitive Behavioural Therapy Group 64 10 
Active Treatment Cognitive Behavioural Therapy Group 64 10 
Waiting List Other N/A - Control 0 0 
Waiting List Other 
 
N/A - Control 0 0 
Van Der Maas 
2015 
Netherlands Neck Pain Active Treatment Multidisciplinary Group Group 112 24 
Control Treatment 1 Multidisciplinary Group Group 97 24 
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First Author & 
Date 
Country Primary Type of 
Pain 
Trial Arm Type of Treatment Intervention 
Format 
 
Dose 
(hours) 
Duration 
(weeks) 
Vlaeyen 1996 Netherlands Fibromyalgia Active Treatment Cognitive Behavioural Therapy Group 42 6 
Control Treatment 1 Education Group 24 6 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Wetherell 2011 United 
States 
Osteoarthritis Active Treatment Acceptance and Commitment Therapy Group 12 8 
Control Treatment 1 Cognitive Behavioural Therapy 
 
Group 12 8 
Williams 1996 United 
Kingdom 
Multiple Sites Active Treatment Cognitive Behavioural Therapy Group 148 4 
Control Treatment 1 Cognitive Behavioural Therapy Group 28 8 
Waiting List No Treatment - Control Group 
 
N/A - Control 0 0 
Zangi 2012 Norway Rheumatoid 
Arthritis 
Active Treatment Mindfulness Programme Group 45 24 
Treatment as Usual Other 
 
N/A - Control NR NR 
Zautra 2008 United 
States 
Rheumatoid 
Arthritis 
Active Treatment Cognitive Behavioural Therapy Group 16 8 
Control Treatment 1 Mindfulness Programme Group 16 8 
Control Treatment 2 Education Group 16 8 
N/A = Not applicable; NR = Not reported; TAU = Treatment as usual. 
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Table 3.2. Participant characteristics summarised by treatment condition. 
 No. of Studies 
Providing     
Data* 
Active Treatment Active Control TAU / WLC 
 
Mean Range SD Mean Range SD Mean Range SD 
Age 51 49.9 34.2-81.9 8.8 50.7 35.6-81.8 9.0 51.1 35.2-75.0 8.3 
Female (%) 53 77.0 12.0-100 20.6 72.1 5.5-100 19.4 77.3 29.0-100 18.6 
Married (%) 32 69.7 17.3-100 19.3 68.6 8.0-100 20.2 68.2 11.5-91.7 17.6 
High School Educated (%) 35 67.3 18.0-100 23.3 64.1 7.0-100 26.5 69.9 12.0-100 28.6 
Employed (%) 34 48.6 9.1-100 28.0 53.3 5.0-100 31.0 41.4 3.0-100 26.2 
Unemployed (%) 18 26.9 0-90.9 30.2 22.8 0-94.10 27.7 29.5 0-93.4 35.1 
Social Benefits (%)** 26 18.3 0-98.0 20.7 13.2 0-65 15.9 25.7 0-79.0 19.4 
Pain Duration (Years) 34 9.8 1.3-34.5 7.1 8.6 1.1-33.9 6.4 12.4 3.5-32.8 7.0 
*Number of studies providing data for each arm of the trial out of 64. 
**Percentage of participants on social benefits or a disability pension. 
TAU = Treatment as Usual; WLC = Wait List Control.
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3.3 Treatment Characteristics 
3.3.1 Overview of treatment and control conditions 
Of the 64 included studies, 43 had two conditions, 16 had three conditions, and five had 
four conditions. Most studies had at least one active control condition (n = 46). TAU and/or 
WLC conditions were used in 34 trials. In total, there were 152 arms across the 64 trials.  
Manualisation 
Active treatment and active control conditions were reported as being manualised in 
62% of conditions. However, less than half of these reported measuring treatment fidelity in 
relation to the manual, such as listening to recordings of treatment sessions (42%).  
Treatment format (group vs. individual) 
Nearly two thirds of active conditions were group interventions (64%). Individual 
interventions were reported in 27% of active conditions. Treatment delivery was not specified 
for 9% conditions. These were typically ‘treatment as usual’ conditions, so a reasonable 
assumption is that they were individual interventions. Mean group size was only reported for 
30% of group interventions. The mean number of participants per group for those reporting data 
was 10 (SD = 5, Range = 5-19). The mean range of group sizes was reported more frequently 
(55% of arms), the mean range was 5 – 9 participants per group. 
3.3.2 Types of treatment delivered 
A wide range of treatments were delivered across the active conditions. I initially 
extracted treatment names verbatim. This resulted in 106 different treatment types. This number 
was high because there were often slight variations in descriptions of what appeared to be 
similar interventions. For example, CBT was labelled in 10 different ways across 20 studies, 
such as: CBT + Pain Avoidance, CBT + Distraction, CBT + Treatment as Usual. To enable a 
useful exploration of these data, I categorised these treatments into one of 13 treatment types. 
To continue with the example of CBT above, I categorised each of those labels as ‘CBT’. 
Figure 3.1 shows the frequency of each treatment type across active conditions. The most 
commonly used treatment was described as CBT (27%), followed by multidisciplinary groups 
(17%), and physiotherapy / exercise based interventions (8%) that were used as active control 
interventions. A total of 14% of trial arms were classified as ‘other’ because they were reported 
infrequently and could not be classified into a broader category, such as Intensive Short-Term 
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Dynamic Psychotherapy (ISTDP), which was present in one study (Chavooshi et al., 2016). The 
‘other’ category also includes treatment as usual conditions that could not be classified into a 
particular treatment type due to lack of specific reporting. 
 
Figure 3.1. Frequency of each treatment type across active conditions. 
3.4 Treatment Components 
3.4.1 Overview of treatment components used 
Figure 3.2 shows the total frequency with which each treatment component was used. 
Homework and psychoeducation were the most frequently used components, both being 
described in 45% of conditions. Relapse prevention and mindfulness were the least frequently 
used interventions (16% and 12% of conditions, respectively). 
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Figure 3.2. Frequency of each treatment component across all active conditions. 
3.4.2 Breakdown of components by treatment and control conditions  
When looking at the treatment components delivered across different conditions, more 
components were delivered in active treatment conditions (M = 6, SD = 2, Range = 0-11) than 
active control conditions (M = 3, SD = 2, Range = 1-6). This difference is interesting because 
one might expect that active control conditions would have been comparable to active treatment 
conditions.  
Treatment as usual conditions rarely reported what treatment was delivered. When 
treatment was described, only four treatment components (out of the total of 13 components) 
were described at all. They were: homework, psychoeducation, exercise and non-psychological 
education. As expected, no treatment components were described for those allocated to the wait 
list control trial condition.   
3.4.3 Breakdown of components used by ‘treatment type’  
When exploring treatment components as a factor of different treatment types, two 
findings emerged that illustrate the complexity of the interventions and the degree of individual 
variation between trials: (1) different interventions often used similar treatment components, 
and (2) similar treatments used different components. I have attempted to demonstrate both 
findings below. Firstly, Figure 3.3 displays how often homework (the most frequently reported 
component) was used by different treatments. It highlights that only two treatments were 
consistent in the way that they described using homework; relaxation and medication / medical 
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visits. There was no such consistency across other treatments. For example, while two thirds of 
the active conditions that stated they were using CBT included homework (67%), this means a 
third of trials using CBT did not include homework (or, importantly, failed to report that they 
included it). A further observation to make of Figure 3.3 is that there are striking similarities 
between different treatments in the proportions of trials using homework. As an example, 71% 
of mindfulness programmes reported including homework, which is similar to the 67% of CBT 
trials. Furthermore, we might expect homework to be included in 100% of both mindfulness and 
CBT trials.  
Secondly, Table 3.3 presents a checklist of whether each treatment component was 
present across all active treatments. This table highlights that while there are some components 
that are consistently used in treatments, such as the use of cognitive strategies in all ACT trials, 
there is notable variation in others, for example, not all ACT trials included a relapse prevention 
component.  
Taken together, this suggests that broad treatment type labels may be of little utility in 
attempting to understand what treatment components were included in the treatment protocol.  
 
 
Figure 3.3. Frequency of homework used as a component of each treatment type. 
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Table 3.3. Checklist of included components for each active treatment across all included trials. 
First Author Treatment Type 
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Kemani ACT 	   	  	 	 	  	 	  	 
Luciano ACT 	   	  	 	 	   	 	  
McCracken ACT 	   	 	 	 	 	 	 	 	 	 	 
Thorsell ACT 	   	 	 	 	 	   	  	 
Geraets Behavioural 	  	 	 	 	   	 	 	 	 	 
Leeuw Behavioural 	  	 	  	 	  	 	 	 	 	 
Nicassio Behavioural 	  	 	  	 	  	 	 	 	  
Thieme Behavioural 	  	 	  	 	 	  	 	 	 	 
Basler CBT     	  	  	  	 	 	 
Castro CBT 	 	 	  	 	 	 	 	 	  	  
Evers CBT 	   	 	 	 	   	   	 
Falcao CBT 	 	  	  	 	 	  	 	 	  
Glombiewski CBT    	  	 	   	 	   
Greco CBT 	 	   	 	 	 	  	  	  
Haldorsen CBT 	 	 	 	  	  	 	  	 	  
Hammond CBT 	 	 	 	      	  	 	 
Karlsson CBT 	     	 	 	    	  
Kerns CBT 	     	  	 	 	 	   
Kraaimaat CBT    	 	  	   	 	 	  
Litt CBT 	 	  	  	 	 	  	 	 	  
McCarberg CBT  	        	  	 	 
Mishra CBT      	 	 	  	 	   
 48 
First Author Treatment Type 
A
tt
en
tio
n 
M
an
ag
em
en
t
B
eh
av
io
ur
  
St
ra
te
gi
es

C
og
ni
tiv
e 
St
ra
te
gi
es

C
om
m
un
ic
at
io
n
Ps
yc
ho
ed
uc
at
io
n
N
on
-
Ps
yc
ho
lo
gi
ca
l 
E
du
ca
tio
n
E
xe
rc
is
e
G
oa
l S
et
tin
g
H
om
ew
or
k
M
in
df
ul
ne
ss

Pr
ob
le
m
 S
ol
vi
ng

R
el
ap
se
 P
re
ve
nt

R
el
ax
at
io
n
Nicholas 2014  CBT 	   	  	 	   	 	 	 	 
Puder CBT  	  	  	 	 	  	 	 	  
Sharpe CBT  	    	 	  	 	  	  
Siemonsma CBT 	   	 	 	 	 	 	 	 	 	 	 
Sleptsova CBT 	 	 	 	  	  	 	 	 	 	 	 
Turner CBT 	 	  	  	    	 	   
Van Koulil CBT 	  	 	 	 	    	 	   
Vlaeyen CBT   	 	      	 	 	 	 
Wetherell CBT 	   	 	 	 	    	 	 	 
Williams CBT 	   	     	 	    
Zautra CBT 	   	  	 	 	  	    
Bennell Coping Skills    	  	  	  	  	 	 
Broderick Coping Skills    	 	 	 	 	  	 	 	  
Keefe 1990 Coping Skills    	  	 	 	  	 	 	  
Keefe 1996 Coping Skills     	  	   	 	 	  
Somers Coping Skills    	   	 	  	 	   
Altmaier MDT Group 	   	  	  	  	 	 	  
Amris MDT Group 	  	   	  	 	 	 	 	  
Bliokas MDT Group 	         	  	  
Castel MDT Group 	     	    	 	   
Ehrenborg MDT Group 	 	 	 	  	  	 	  	 	  
Heutink MDT Group 	 	 	   	 	  	 	 	 	  
Jensen 2001 MDT Group   	         	  
Jensen 1997 MDT Group 	 	    	   	 	  	  
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Khan MDT Group 	   	 	 	  	  	  	 	 
Martin MDT Group 	     	  	  	 	 	  
Monticone MDT Group    	  	  	  	 	 	 	 
Monticone MDT Group    	  	  	 	 	 	 	 	 
Nicholas 2013 MDT Group 	     	    	   	 
Smeets MDT Group 	  	 	  	    	  	 	 
Tavafian MDT Group 	   	    	 	 	 	 	  
VanDerMaas MDT Group 	        	  	 	  
Cash Mindfulness   	 	 	 	 	  	   	 	 	 
Chavooshi Mindfulness  	 	 	 	 	 	 	 	 	 	 	 	 	 
Cherkin Mindfulness  	 	 	 	 	 	  	   	 	 	 
Schmidt Mindfulness  	 	 	 	 	 	     	 	 	 
Zangi Mindfulness   	  	 	 	 	 	   	 	  
Ersek Other 	   	      	 	   
Poleshuck Other 	  	 	 	 	 	  	 	 	 	  
Scheidt Other 	 	 	 	 	 	 	 	 	 	 	 	 	 
Turner Other 	 	  	 	 	 	 	  	 	 	  
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3.5 Overview of Treatment Dose  
There was considerable variability in the number of hours delivered. Of a total of 152 
treatment and control conditions, 139 provided information on dose measured in hours. The 
median number of hours was 16 (Range = 0-200). The lower range of 0 is explained by some 
control conditions being interventions such as ‘standard pharmacologic treatments’.. In total, 
29% of conditions were 25 hours or longer. The longest interventions on average were active 
treatments, with a median of 20 hours (Range 6-200). Active control conditions were shorter 
than treatment conditions (Median = 18, Range = 0-200). With the exception of one trial, data 
about dose was not reported for TAU conditions. Scheidt et al. (2013) reported that TAU was 
approximately one hour of consultation with participants’ primary physician (spread over four 
consultations).  
Variability was also substantial in terms of the number of weeks over which treatment 
was delivered. In total, 144 conditions reported their duration in weeks (out of a possible 152). 
The median number of weeks was 8 (Range = 0-36). Again, active treatments were the longest 
(Median = 8, Range = 2-36), but active control conditions were comparable in terms of length 
(Median = 8, Range = 0-36). TAU conditions were shorter (Median = 0, Range = 0-24).  
The large range of treatment dose variation in both hours and timescale for delivery 
lends further support for the use of meta-regression as a tool to investigate dose as a predictor of 
change.  
3.6 Meta-Analyses  
I completed two meta-analyses; comparing active treatment with active control, and 
comparing active treatment with TAU / WLC. Neither analyses included any additional 
moderators. This section will provide an overview of the findings from this analysis, broken 
down by outcome domain. Table 3.4 shows the number of studies and number of participants 
included in analyses for each outcome domain. See Appendix B and Appendix C for 
comprehensive results tables of meta-analysis results by outcome domain. 
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Table 3.4. Number of studies and participants included in each comparison for each outcome 
domain. 
  
Active treatment vs. 
active control  
Active treatment vs.  
TAU / WLC 
Outcome Domain  Number of Studies 
Number of 
Participants  
Number 
of Studies 
Number of 
Participants  
Pain Experience 38 1712 28 1398 
Pain Behaviour  12 608 5 197 
Emotional Functioning 35 1611 25 1234 
Physical Functioning 38 1701 28 1402 
Coping & Cognitive Appraisal 24 1073 17 127 
 
3.6.1 Active treatment compared with active control 
The forest plot shown in Figure 3.4 summarises the effect sizes (Hedges’ g) for the 
difference between active treatment and active control conditions, along with 95% CIs. 
Outcomes favoured the active treatment condition, with small to moderate effects. The largest 
effect was for the coping and cognitive appraisal outcome domain, however; large confidence 
intervals suggest caution is needed in interpreting this result.  
The difference between the active treatment and active control conditions was not 
statistically significant for pain experience (Hedges’ g = 0.31, p = 0.057, ns) nor coping and 
cognitive appraisal (Hedges’ g = 0.58, p = 0.11, ns). Effect sizes were statistically significant for 
pain behaviour (Hedges’ g = 0.28, p < 0.05), emotional functioning (Hedges’ g = 0.27, p < 
0.05), and physical functioning (Hedges’ g = 0.31, p < 0.05). Heterogeneity was high for 
analyses across all outcome domains (Mean I2 = 99.36%, Range = 98.04 – 100%).  
 
Figure 3.4. Forest plot of effect sizes (Hedges’ g) for active treatment vs. active control 
conditions. 
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3.6.2 Active treatment compared with TAU / WLC 
The forest plot shown in Figure 3.5 summarises Hedges’ g effect sizes for the 
difference between active treatment and TAU / WLC conditions, along with 95% CIs. 
Outcomes were again more favourable for the active treatment condition than the control 
condition, with similar effect sizes as when active treatment was compared with active control: 
small to moderate.  
The difference between active treatment and TAU / WLC conditions was not 
statistically significant for pain experience (Hedges’ g = 0.39, p = 0.062, ns). However, effect 
sizes were statistically significant for pain behaviour (Hedges’ g = 0.36, p < 0.05), emotional 
functioning (Hedges’ g = 0.24, p < 0.01), physical functioning (Hedges’ g = 0.12, p < 0.05), and 
coping and cognitive appraisal (Hedges’ g = 0.38, p < 0.001). Heterogeneity was high again for 
all analyses across all outcome domains (Mean I2 = 98.55%, Range 96.57% - 99.94%).  
 
Figure 3.5. Forest plot of effect sizes (Hedges’ g) for active treatment vs. TAU / WLC control 
conditions. 
 
3.6.3 Publication bias 
The fail-safe N was 9,637 for active treatment compared with active controls, and 9,197 
for active treatment compared with TAU/WLC. These fail-safe N values are high, and suggest 
that the potential impact of publication bias is likely to be minimal on the results presented here.  
3.7 Meta-regression Analyses: The ‘Dose-Response’ Question  
In this section I will describe the findings of meta-regression analyses using dose in 
hours, followed by dose in weeks as predictors. I present summary data in tables, and graphical 
displays for statistically significant relationships.  
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3.7.1 Dose in hours and response 
Active treatment compared with active control 
When comparing active treatment with active control conditions, magnitude of change 
did not vary significantly by dose in hours across any outcome domain. Table 3.5 presents the 
regression coefficients across all outcome domains for dose in hours as a predictor. Thus, the 
coefficient represents the interaction between the effect and dose in hours. A negative 
coefficient indicates that treatment is less effective as the level of the predictor decreases.  
Recall that the conventional 0.05 level of significance can be relaxed to 0.2 for the purposes of 
generating hypotheses. Despite this adjustment, there were no statistically significant 
relationships.  
Active treatment compared with TAU / WLC 
Similarly, when comparing active treatment with TAU / WLC, magnitude of change did 
not vary significantly by dose in hours across any outcome domain. Table 3.6 presents the 
regression coefficients across all outcome domains for dose in hours as a predictor.  
3.7.2 Timescale of intervention (dose in weeks) and response 
Active treatment compared with active control 
When comparing active treatment with active control conditions, magnitude of change 
did not vary significantly by dose in weeks across any outcome domain. Table 3.7 presents the 
regression coefficients across all outcome domains for dose in weeks as a predictor.  
Active treatment compared with TAU / WLC 
In contrast, dose in weeks was significantly associated with increased effect sizes 
(Hedges’ g) for pain experience (β = 0.04, p < 0.2), and coping and cognitive appraisal (β = 
0.01, p < 0.2) when active treatments were compared with TAU / WLC. This means that for 
every additional week over which treatment was delivered, there was an estimated increase in 
effect size of 0.04 and 0.01 for pain experience and coping and cognitive appraisal, respectively. 
Figure 3.6 and Figure 3.7 display this finding, where each circle represents a trial and the area 
of each circle is the weight given to that trial (based on the inverse of its variance). The close 
clustering of trials around the line for pain experience suggests that we can be confident in the 
assertion that pain dose in weeks is associated with pain experience. In contrast, the dispersion 
of trials away from the line for coping and cognitive appraisal suggests that more caution is 
required when interpreting the association between dose in weeks and effect size for this 
domain.  For other outcome domains, effect size did not vary significantly by dose in weeks. 
Table 3.8 presents the regression coefficients across all outcome domains for dose in weeks as a 
predictor.  
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Figure 3.6. Dose in weeks and Hedges' g for pain experience – Active treatment vs. TAU / 
WLC. 
 
Figure 3.7. Dose in weeks and Hedges' g for coping and cognitive appraisal – Active treatment 
vs. TAU / WLC. 
3.7.3 Interim comment on the ‘dose-response’ question 
In sum, there is limited evidence of a clear linear relationship between dose and 
magnitude of change. Dose in hours was not significantly associated with increasing effect sizes 
for any outcome domains. This was true when active treatments were compared with active 
controls, and when they were compared with TAU / WLC control groups. The only significant 
association found was for coping and cognitive appraisal, and pain experience when active 
treatment was compared with TAU / WLC. For these two outcome domains, treatments lasting 
for more weeks were related to greater change.  
Heterogeneity was high across all analyses, suggesting that there is variability between 
studies that is not related to chance. I completed meta-regression analyses for three participant 
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demographic predictors to explore whether they were associated with magnitude of change. The 
three predictors chosen were: percentage of females, age of participants, and duration of pain (in 
years). I chose these because they have all been subject to analyses in previous analyses of 
psychological interventions for chronic pain. Although there were a number of further 
participant demographic predictors that I could have used as well, I restricted my analyses to 
these three predictors to avoid data mining.  
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Table 3.5. Dose in hours: regression coefficients by outcome domain – active treatment compared with active control. 
Active treatment vs. active control  
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 37 1636 -0.002 0.004 0.56 -0.011 0.006 99.83% 0.991 
Pain Behaviour  12 608 0.004 0.004 0.27 -0.004 0.013 98.20% 0.170 
Emotional Functioning 34 1535 -0.002 0.003 0.47 -0.007 0.003 99.39% 0.430 
Physical Functioning 37 1625 -0.003 0.003 0.39 -0.009 0.003 99.58% 0.688 
Coping & Cognitive Appraisal 23 997 -0.003 0.009 0.69 -0.021 0.014 99.99% 3.181 
β = regression coefficient  
 
 
 
Table 3.6. Dose in hours: regression coefficients by outcome domain – active treatment compared with TAU / WLC. 
Active treatment vs. TAU / WLC 
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 26 1355 -0.004 0.007 0.56 -0.018 0.010 99.94% 1.222 
Pain Behaviour  5 197 0.010 0.008 0.29 -0.015 0.036 96.14% 0.040 
Emotional Functioning 23 1191 -0.001 0.002 0.79 -0.006 0.004 99.26% 0.151 
Physical Functioning 26 1359 0.000 0.002 0.87 -0.004 0.003 98.19% 0.077 
Coping & Cognitive Appraisal 16 753 0.003 0.004 0.47 -0.005 0.011 97.64% 0.080 
β = regression coefficient  
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Table 3.7. Dose in weeks: regression coefficients by outcome domain – active treatment compared with active control. 
Active treatment vs. active control  
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 37 1660 0.019 0.025 0.44 -0.031 0.069 99.82% 0.979 
Pain Behaviour  12 608 -0.001 0.019 0.96 -0.044 0.042 98.21% 0.194 
Emotional Functioning 34 1559 -0.004 0.016 0.79 -0.036 0.028 99.37% 0.433 
Physical Functioning 37 1649 -0.002 0.020 0.94 -0.042 0.039 99.58% 0.702 
Coping & Cognitive Appraisal 23 1021 0.018 0.064 0.79 -0.115 0.150 100.00% 3.206 
β = regression coefficient  
 
 
 
Table 3.8. Dose in weeks: regression coefficients by outcome domain – active treatment compared with TAU / WLC. 
Active treatment vs. TAU / WLC 
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 27 1345 0.041 0.029 0.17 -0.019 0.100 99.93% 1.115 
Pain Behaviour  5 197 -0.014 0.012 0.32 -0.050 0.023 93.68% 0.042 
Emotional Functioning 24 1181 0.001 0.008 0.93 -0.016 0.018 98.62% 0.095 
Physical Functioning 27 1349 0.006 0.008 0.45 -0.010 0.023 97.78% 0.088 
Coping & Cognitive Appraisal 16 721 0.014 0.010 0.18 -0.007 0.035 98.81% 0.095 
β = regression coefficient  
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3.8 Meta-regression Analyses: Patient Characteristics   
In this section I will describe the findings of meta-regression analyses using participant 
characteristics as predictors. As discussed in my introduction, there are a number of 
characteristics that could have been explored. I chose to analyse three characteristics to limit the 
possibility of spurious results due to multiple analyses. Age and gender were chosen because 
they have been analysed in previous trials with mixed results (Waterschoot et al., 2014; 
Hoffman et al., 2007; Glombiewski et al., 2010). I chose pain duration because it has been 
highlighted as a characteristic that merits investigation but there has been insufficient data to 
enable this until now (Waterschoot et al., 2014; Hoffman et al., 2007). Again, I present all 
summary data in tables, and graphical displays for statistically significant relationships.  
3.8.1 Percentage of females 
Active treatment compared with active control 
When comparing active treatment with active control conditions, magnitude of change 
did not vary significantly by percentage of females across any outcome domain. It appears that 
percentage of females was approaching significance for pain behaviour (β = 0.006, p = 0.2, ns). 
This relationship is displayed in Figure 3.8. The relatively small number of studies included in 
this analyses may be a reason why this did not reach statistical significance. Table 3.9 presents 
the regression coefficients across all outcome domains for percentage of females as a predictor.  
Active treatment compared with TAU / WLC 
Interestingly, the percentage of females was less associated with magnitude of change 
for pain behaviour when active treatment was compared with TAU / WLC (β = 0.01, p = 0.43, 
ns), although it may be important to note that only four studies provided data that were 
analysable here, in contrast to 10 studies that provided data on active treatment and active 
control for pain behaviour. There were also no significant associations between percentage of 
females and outcome for emotional functioning or physical functioning. However, magnitude of 
change was significantly associated with percentage of females for pain experience (β = 0.005, p 
< 0.2) and coping and cognitive appraisal (β = 0.01, p < 0.05). This indicates that for every 
additional 10% of females included, effect sizes increase by an estimated 0.05 for pain 
experience and 0.1 for coping and cognitive appraisal. Figure 3.9 and Figure 3.10 visually 
present this association. Table 3.10 presents the regression coefficients across all outcome 
domains for percentage of females as a predictor.  
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Figure 3.8. Percentage of females and Hedges' g for pain behaviour – Active treatment vs. 
active control. 
 
 
Figure 3.9. Percentage of females and Hedges' g for pain experience – Active treatment vs. 
TAU/WLC. 
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Figure 3.10. Percentage of females and Hedges' g for coping and cognitive appraisal – Active 
treatment vs. TAU/WLC. 
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Table 3.9. Percentage of females: regression coefficients by outcome domain – active treatment compared with active control. 
Active treatment vs. active control  
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 30 1439 0.004 0.005 0.51 -0.007 0.014 99.32% 0.404 
Pain Behaviour  10 544 0.006 0.004 0.20 -0.004 0.016 97.92% 0.115 
Emotional Functioning 30 1434 0.001 0.005 0.93 -0.011 0.012 99.39% 0.427 
Physical Functioning 30 1420 -0.001 0.003 0.70 -0.008 0.005 98.32% 0.148 
Coping & Cognitive Appraisal 19 874 -0.013 0.024 0.59 -0.064 0.037 99.99% 3.197 
β = regression coefficient  
 
 
 
Table 3.10. Percentage of females: regression coefficients by outcome domain – active treatment compared with TAU / WLC. 
Active treatment vs. TAU / WLC 
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 23 1270 0.005 0.004 0.19 -0.003 0.013 98.92% 0.167 
Pain Behaviour  4 176 0.011 0.012 0.43 -0.038 0.061 97.55% 0.063 
Emotional Functioning 22 1165 0.005 0.004 0.21 -0.003 0.013 98.92% 0.147 
Physical Functioning 24 1294 0.001 0.003 0.68 -0.004 0.006 98.32% 0.148 
Coping & Cognitive Appraisal 14 688 0.010 0.003 0.02 0.002 0.017 98.76% 0.074 
β = regression coefficient  
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3.8.2 Age  
 Active treatment compared with active control 
When comparing active treatment with active control conditions, magnitude of change 
did not vary significantly by mean age of participants across any outcome domain. Table 3.11 
presents the regression coefficients across all outcome domains for age as a predictor.  
Active treatment compared with TAU / WLC 
Similarly, when comparing active treatment with active control conditions, magnitude 
of change did not vary significantly by mean age of participants across any outcome domain. It 
appears that age was approaching significance for pain experience (β = 0.015, p = 0.25, ns) and 
pain behaviour (β = -0.024, p = 0.24, ns). Although this result was non-significant, the trend is 
interesting as a pair of results because it suggests that the older the participants, they are 
simultaneously more likely to improve in terms of pain experience and less likely to improve in 
pain behaviour. These trends are displayed in Figure 3.11 and Figure 3.12. 
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Figure 3.11. Age and Hedges' g for pain experience – Active treatment vs. TAU/WLC. 
 
Figure 3.12. Age and Hedges' g for pain behaviour – Active treatment vs. TAU/WLC.
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Table 3.11. Age: regression coefficients by outcome domain – active treatment compared with active control. 
Active treatment vs. active control  
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 30 1439 0.008 0.011 0.49 -0.015 0.030 99.33% 0.403 
Pain Behaviour  10 544 -0.010 0.012 0.44 -0.037 0.017 98.08% 0.132 
Emotional Functioning 30 1434 -0.002 0.011 0.89 -0.025 0.022 99.38% 0.427 
Physical Functioning 30 1420 0.004 0.007 0.58 -0.010 0.018 98.31% 0.147 
Coping & Cognitive Appraisal 14 874 -0.018 0.035 0.61 -0.093 0.056 100% 3.205 
β = regression coefficient  
 
 
 
Table 3.12. Age: regression coefficients by outcome domain – active treatment compared with TAU / WLC. 
Active treatment vs. TAU / WLC 
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 21 1200 0.015 0.013 0.25 -0.012 0.042 99.26% 0.186 
Pain Behaviour  4 176 -0.024 0.014 0.24 -0.086 0.038 96.51% 0.038 
Emotional Functioning 21 1135 -0.001 0.013 0.97 -0.028 0.027 99.34% 0.166 
Physical Functioning 22 1224 0.005 0.009 0.57 -0.014 0.025 98.42% 0.079 
Coping & Cognitive Appraisal 13 648 0.001 0.016 0.93 -0.034 0.037 98.59% 0.137 
β = regression coefficient  
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3.8.3 Duration of pain 
 Active treatment compared with active control 
When comparing active treatment with active control conditions, magnitude of change 
was significantly associated with duration of pain (measured in years) for physical functioning 
(β = -0.017, p < 0.2), and coping and cognitive appraisal (β = -0.125, p < 0.2). This indicates 
that for every additional year in pain, effect sizes reduce by approximately 0.02 for physical 
functioning, and by 0.13 for coping and cognitive appraisal. Although this may seem like rather 
a small change, considering effect sizes were small to moderate (Hedges’ g typically ranging 
between 0.2 – 0.3), a 0.1 change is a proportionally large statistical change; at least a 33% 
improvement. Figure 3.13 and Figure 3.14 present these associations. There were no other 
significant associations between duration of pain and magnitude of change. Table 3.13 presents 
the regression coefficients across all outcome domains for duration of pain as a predictor.  
Active treatment compared with TAU / WLC 
In contrast, there were no significant associations between magnitude of change and 
duration of pain when active treatment was compared with TAU / WLC. Table 3.14 presents 
the regression coefficients across all outcome domains for age as a predictor.  
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Figure 3.13. Duration of pain and Hedges' g for physical functioning – Active treatment vs. 
active control. 
 
 
Figure 3.14. Duration of pain and Hedges' g for coping and cognitive appraisal – Active 
treatment vs. active control. 
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Table 3.13. Pain duration: regression coefficients by outcome domain – active treatment compared with active control. 
Active treatment vs. active control  
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 20 881 -0.008 0.022 0.71 -0.054 0.038 99.50% 0.550 
Pain Behaviour  6 356 0.004 0.023 0.86 -0.059 0.068 98.91% 0.283 
Emotional Functioning 20 883 0.003 0.022 0.89 -0.043 0.049 99.48% 0.584 
Physical Functioning 19 837 -0.017 0.012 0.17 -0.043 0.008 98.48% 0.174 
Coping & Cognitive Appraisal 11 444 -0.125 0.071 0.11 -0.285 0.035 99.99% 4.447 
β = regression coefficient  
 
 
 
Table 3.14. Pain duration: regression coefficients by outcome domain – active treatment compared with TAU / WLC. 
Active treatment vs. TAU / WLC 
Outcome Domain No. of Studies 
No. of 
Participants 
β 
Coefficient 
Standard 
Error P 
Lower 
CI 
Upper 
CI I
2 !" 
Pain Experience 12 594 -0.015 0.017 0.40 -0.052 0.023 99.26% 0.217 
Pain Behaviour  $ $ $ $ $ $ $ $ $ 
Emotional Functioning 13 617 0.004 0.017 0.83 -0.034 0.042 99.46% 0.235 
Physical Functioning 13 617 0.004 0.009 0.68 -0.016 0.024 95.44% 0.064 
Coping & Cognitive Appraisal 9 462 0.009 0.014 0.52 -0.023 0.041 99.41% 0.112 
β = regression coefficient; $ = not enough studies for analysis   
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4 Discussion 
This thesis replicated and extended the most recent comprehensive Cochrane review of 
psychological interventions for chronic pain (Williams et al., 2012). I extended the previous 
review in three ways: (1) I investigated treatment content within each intervention and created a 
list of treatment components, (2) I included all outcome measures by aggregating data into five 
outcome domains, and (3) I applied sophisticated meta-regression analyses to explore the impact 
of dose on improvement.  
I conducted a total of 60 analyses of data from a total of 7,840 participants across 64 
randomised controlled trials. Active treatments were compared with both active control and 
TAU / WLC control conditions across the five outcome domains. In addition to dose in hours 
and duration of intervention in weeks, I accounted for three participant characteristics as 
potential predictors; percentage of females, age, and duration of pain. To date, this is the largest 
meta-analysis of findings from studies of non-cancer chronic pain (excluding headache).  
The included trials varied in terms of participant characteristics, but on average they 
included more females than men, were middle aged, and were mostly educated to high school 
level. Ethnicity was rarely reported. Trials included a variety of chronic pain diagnoses, such as 
temporomandibular joint disorder, fibromyalgia, chronic low back pain, and arthritis. Although 
it is possible that different types of pain have different treatment trajectories, I did not 
differentiate between different pain types in any of my analyses. The treatments delivered were 
mostly group interventions, and mostly called CBT.  
Risk of bias was relatively low or unclear across all aspects of the Cochrane Risk of 
Bias tool, suggesting that plausible bias is unlikely to seriously alter the results. The highest risk 
of bias was for detection bias, where outcome assessment was not blinded. Although a high risk 
of bias would usually be interpreted as potentially weakening the confidence that one could 
place in the results, it should be noted that as most measures used were self-reported, the impact 
of this bias may be minimal.  
4.1 Meta-analytic Results 
Effect sizes (Hedges’ g) were similar both when comparing active treatments with 
active controls (Mean Hedges’ g = 0.35) and when comparing active treatments with TAU / 
WLC control (Mean Hedges’ g = 0.3) conditions. In both cases, effects were small to moderate 
across all outcome domains. Although the effects were broadly consistent, albeit slightly higher, 
here than in the Williams et al. (2012) review when comparing active treatment with active 
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control. Small differences were expected given the different approaches to including and 
analysing outcome measures.  
One might argue that such modest effect sizes are unimportant. However, as Lipsey and 
Wilson (2001) explain, a small effect size may have significant implications for clinical practice 
because meta-analysis does not take account of the context of the intervention. An intervention 
that has few resources and requires little of participants but brings about a change may be 
clinically meaningful. Baguley (2009) takes this one step further and proposes that verbal 
categorisations of effect sizes (such as ‘small’) are not used because of the critical roles that 
context of treatment and setting play in interpreting change. Indeed, Lepper, Henderlong, and 
Gingras (1999) remind us that “although it may be tempting to succumb to the facile assumption 
that meta-analysis provides clear-cut, objective answers to complex questions, we must resist 
this oversimplification” (p. 675). The exploration of potential moderators may help us to resist 
such oversimplification.  
4.2 Treatment Components 
Two key findings emerged from my investigation of treatment content. First, there was 
disparity between trials in the treatment components used even when the trials appeared to be 
delivering the same type of treatment. Second, treatments that were described as being distinct, 
actually used treatment content that was often similar. For example, homework is considered a 
core part of CBT, and is included in the Cognitive Therapy Rating Scale that is used by 
clinicians and researchers to check adherence to a CBT protocol (Young & Beck, 1980). 
However, my findings suggest that 33.3% of CBT trials do not include homework (or do not 
report that they use homework). Clinical wisdom suggests that this is accurate. Clinicians might 
add a component, say mindfulness, to CBT if they believe it is clinically appropriate. Indeed, a 
recent survey of over 1,000 therapists found that the majority prefer an eclectic approach to 
therapy – only 15% indicated that they use one theoretical orientation (Tasca et al., 2015). 
However, this should not be the case in RCTs, which are highly thought of because they limit 
variation. On the one hand, this may add external validity of the trial’s findings to clinical 
practice, but such variation makes it difficult to be confident in the conclusions about the 
treatment effects. The limitations of RCT methodology to evaluate clinical effectiveness in 
psychological interventions are acknowledged academically. Westen, Novotny and Thompson-
Brenner (2004) highlight that although RCTs may profess to analyse a particular therapy, they 
are actually testing a treatment package and are not testing the specific interventions that make 
up that treatment package. Westen et al. (2004) go on to argue that investigators should move 
away from investigating commonly accepted complete treatment packages (such as CBT) and 
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focus on testing specific interventions; a proposition that goes hand-in-hand with the findings 
that emerged here.  
 To my knowledge, this is the first systematic attempt to establish the variability in the 
components used by psychological treatments for chronic pain. There are two conclusions that 
can be drawn from the findings about treatment components presented here. The first is to be 
cautious when exploring and interpreting any apparent statistical differences between different 
treatment types, for example, whether ACT facilitates more change than CBT. This conclusion 
may reflect limitations of how psychological interventions are evaluated more broadly. Linden 
(2013) describes similar difficulties in the field of psychological interventions in Cardiology, 
such as cardiac rehabilitation following a heart attack. Linden warns that any research 
concluding that differential treatment outcomes were found as a function of treatment type 
“should be approached with considerable mistrust” (p. 333). He also notes that if we are to use 
broad classifications of treatment type (such as ‘CBT’), then we must only do so when we can 
demonstrate reliable, blind classifications with non-overlapping categories. It is clear from the 
findings of this thesis that we are currently a long way from this goal in chronic pain.  
 One potential reason for the use of broad treatment type classifications as the research 
strategy of choice is that it simplifies the complexities of delivering multiple components. In 
their paper on contemporary issues in pain, O’Connell, Moseley, McAuley, Wand, and Herbert 
(2015) remind us of the words of physicist, Richard Feynman: “For a successful technology, 
reality must take precedence over public relations, for Nature cannot be fooled” (p. 1092). This 
resonates with research into psychological treatments, where we have a number of treatment 
types that may be competing, even if not explicitly, to be the ‘lead’ model (McCracken & 
Marin, 2014). We must not succumb to a simple narrative of psychological treatment as neatly 
and consistently packaged in one particular ‘type’, such as CBT. To do so may prevent us from 
developing a more refined understanding of treatment content and outcome. 
4.3 The ‘Dose-Response’ Question 
4.3.1 Summary of findings 
Overall, there was limited evidence for the association between dose and outcome. This 
was especially true when measured in hours, suggesting that the patient’s improvement 
following psychological intervention is not necessarily dependent on the total amount of 
treatment delivered. When dose was measured in weeks, i.e. the period over which treatment 
was delivered, there was a significant association with outcome for two out of five outcome 
domains; coping and cognitive appraisal, and pain experience. This association was only found 
when the active treatment was compared with TAU / WLC, not when active treatment was 
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compared with active control. There were studies that brought about improvement with 
relatively few weeks and hours of treatment and others that facilitated relatively little change 
despite many weeks of treatment. As an example, Nicassio et al. (1997) delivered 15 hours of 
treatment over 10 weeks and participants improved in emotional functioning (Hedges' g = 0.47). 
In contrast, Sleptsova, Woessmer, Grossman, and Langewitz (2013) found much smaller effects 
(Hedges’ g = 0.02) despite 37.5 hours of treatment over 24 weeks. These findings are broadly 
similar to those presented by Waterschoot et al. (2014), who also reported differential 
associations between dose and response as a factor of type of outcome (disability, work 
participation and quality of life). In contrast, my findings contradict those by Glombiewski et al. 
(2010) where dose in hours was found to be related to reductions in pain intensity and 
depression. The authors concluded that patients with fibromyalgia should be offered high doses 
of CBT, a conclusion that cannot be supported based on findings here.  
There may be statistical reasons for the lack of support for a relationship between dose 
and outcome. One reason may be the ‘range restriction problem’. This is caused by the limited 
range of small effect sizes resulting in little opportunity to detect true effects (Linden, 2013). 
Moreover, the Cochrane Handbook for Systematic Reviews also explains that stating that a 
dose-response relationship does not exist should be done only with caution because of the 
potential for underpowered results (Higgins & Green, 2011). Taken together, the findings from 
this thesis do not seem to support the notion that treatment outcomes improve as the amount of 
treatment increases. This is contrary to what would be predicted in line with the traditional dose-
response concept. Nevertheless, further statistical analyses using different research methods are 
required before we should firmly conclude that a dose-response relationship does not exist.  
4.3.2 Alternatives to the dose-response concept 
To fully critique the dose-response concept, we must explore its underlying 
assumptions. Arguably, the two most important assumptions made by the concept of dose-
response are inter-related; that the more treatment is given, the bigger effects one ought to see 
and that this pattern will be consistent across patients. However, such assumptions cannot be 
fully supported by the evidence presented here. On the whole, treatment effects did not get 
bigger the more treatment was given. Moreover, as I will discuss shortly, it is unlikely that the 
relationship between dose and outcome will be the same across patients because some patient 
characteristics were related to differential amounts of change. 
 There are a number of reasons why the relationship between dose and outcome is not as 
simple as ‘the more the better’. One might hypothesise, for example, that longer interventions 
are more intensive and thus lead to less adherence, or that participants who are more anxious 
will require longer therapy whereas those who are less anxious may respond more quickly. In 
 72 
the broader field of psychotherapy, research has attempted to shed light on whether there is a 
non-linear relationship between dose and outcome. Particularly interesting is an alternative to 
the ‘dose-response’ concept of change proposed by Barkham and colleagues (2006). The ‘Good 
Enough Level’ model of change (GEL) places less importance on the total number of sessions, 
and posits instead that clients are generally inclined to stay in therapy until they have benefited 
from it, that is, until they feel ‘good enough’. This implies that rather than there being one 
pattern of change in response to dose, there are several patterns of change and patients are active 
agents in this. This notion certainly has face validity. We know that the right amount of 
medication for one person may be an overdose or an underdose for another person (Kazdin, 
2007). In addition to face validity, there is empirical support for the idea of patient specific 
patterns of change.  
Owen et al. (2015) found three patterns of change when they investigated the GEL 
model in relation to psychological functioning following short-term (up to 14 sessions) 
psychotherapy. The first pattern was early change followed by a plateau, the second was initial 
decrease followed by a rapid increase and the third was a linear and steady increase over 
sessions. What differentiates the participants who might follow each pattern requires further 
exploration. Owen and colleagues found that those following the initial decrease then rapid 
increase in functioning pattern were more distressed on entry. Furthermore, Reese, Norsworthy, 
and Rowlands (2009) found that frequency of sessions was related to change; such that students 
who attended a university counselling service for more sessions per week demonstrated more 
rapid improvement than those who attended for the same number of sessions over a longer 
period of time. In sum, the GEL presents an alternative way of thinking about the relationship 
between dose and response. The GEL model is more comprehensive in that it would enable 
testing of patient characteristics, frequency of treatment delivery as well as ‘amount’ of 
treatment. Having said that, a significant shift in current research paradigms is needed before we 
can robustly investigate how the GEL model relates to change following psychological 
interventions for chronic pain. As it stands, trials rigidly apply a dose that all participants 
receive. This means that participants cannot simply attend until they feel as though they have 
benefited enough. Or, indeed, cannot continue in therapy if they still need further support past 
the allocated ‘dose’ of therapy. One approach to overcoming this would be to use different 
research methods. One promising method is the single case design, which I will describe 
shortly.  
4.3.3 Patient characteristics and outcome 
I found that some characteristics may be related to magnitude of change. Percentage of 
females was related to change in outcomes for pain experience and coping and cognitive 
appraisal. This finding complements those of Hoffman et al. (2007), where the percentage of 
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males in trials was associated with smaller effects. I also found that the length of time that 
participants had been living with pain (i.e. pain duration) was associated with improvement in 
physical functioning and coping and cognitive appraisal. This suggests that these characteristics 
are important for further research. Age seemed unrelated to outcome but there are several 
reasons why this may be the case. It is important to consider these reasons because they also 
have relevance to our interpretation of the lack of evidence for the dose-response question. 
To account for these three patient characteristics in my analyses, I extracted mean data 
from each trial. However, it is possible that this overlooks within-trial effects. Thompson and 
Higgins (p. 1564; 2002) describe and illustrate this well; “the relationship with patient averages 
[and treatment effect] across trials may not be the same as the relationship for patients within 
trials”. Figure 4.1 replicates a figure from their paper (p. 1564). The lines show within-trial 
treatment effects, and circles represent the relationship between trials. The top graph 
demonstrates that within each trial there is a relationship between age and treatment effect, but 
this would not be identified if you were to look for a relationship in the mean scores across 
trials. In contrast, the bottom graph shows that there is no relationship between age and effect 
within each trial, but there would appear to be a relationship looking across trials. This 
phenomenon can be thought of as the ‘aggregation bias’ (Morgenstern, 1982), and cannot be 
explored without data at the patient level, rather than the trial level (Thompson & Higgins, 
2002).  
A further challenge of exploring the relationship between patient characteristics and 
outcome is that research trials do not always publish comprehensive accounts of participant 
characteristics. For example, despite the potentially important influence of taking medication 
while receiving psychological interventions authors rarely reported on medication use. This 
means that we might be reporting participant characteristics (such as age) that bear little 
weighting on outcome while missing other relevant characteristics altogether. A further example 
is that there may be a meaningful psychological (as well as functional) difference between 
someone living with chronic pain who is ‘employed’ and working full time, and someone who 
is ‘employed’ but working one day per week. At best, trials currently report the percentage of 
participants ‘employed’, with only a select few specifying ‘full time’ or ‘part time’. To advance 
the study of psychological interventions for chronic pain and allow greater specificity of 
analyses, more detailed reporting of participant characteristics is required. This ought to include 
the number and type of previous treatments for chronic pain (such as use of spinal cord 
stimulator, physiotherapy etc.), ethnicity, medication use. Reporting such nuances is not 
common practice, but would facilitate better analyses and aid our understanding of mechanisms 
of change in psychological interventions for chronic pain.  
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Figure 4.1. Hypothetical relationship between age and treatment effect both within trials 
(represented by the lines) and between trials represented by the dots (taken from Thompson & 
Higgins, 2002; p. 1564).  
 
4.4 Implications for Research  
4.4.1 Implications for dose-response 
There are two potential hypotheses that may be generated from my findings:   
1. The longer the intervention (in weeks), the greater the improvement in pain 
experience, and coping and cognitive appraisal outcomes.  
2. There is a non-linear relationship between dose (in hours) and outcome.   
To test these hypotheses in a robust manner, it is crucial that we do not overly rely on 
the RCT as a research design. Moving away from RCTs has long been advocated as a strategy 
for the field of psychological interventions for chronic pain. Perhaps the strongest campaign for 
change was Morley, Williams, and Eccleston's (2013) call for a paradigm shift. Among several 
suggestions for innovation in the field, they proposed that single case study designs and analysis 
of patient level data may be prudent approaches to enhance our knowledge. I will now outline 
how these two methodologies may help better understand and potentially resolve the issues 
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raised in this thesis. I will also describe recommendations for the continued study of treatment 
components as well as treatment types.  
Single-case studies 
Single case studies, or single case series, are characterised by the repeated measurement 
of individual patients over time; often before, during and after an intervention (McMillan & 
Morley, 2010). For some time, they have been considered the ‘poor cousin’ of the RCT 
(Morley, in press), however, the findings of this thesis add to the argument that they should have 
a high place on the research agenda. Synthesising data about how treatment dose relates to 
outcome in primary studies has yielded little in the way of clear evidence. Single-case studies 
would allow us to explore potential relevance of the ‘good enough level’ models of dose. The 
frequent assessments of change over time would enable us to explore whether there are ‘rapid 
responders’ to psychological interventions. Over time, this would allow us to profile participants 
and perhaps offer particular components of treatments based on psychological profiles rather 
than chronic pain diagnoses, which may be unrelated to the extent to which a patient is 
struggling or in distress (Williams et al., 2012). This suggests that single-case studies would 
help us to learn more about dose-effect relationships and build on the tentative hypotheses 
generated here.  
Patient-level data 
Patient-level data may help us to overcome the aggregation bias mentioned earlier, 
where important variation within trials is not represented by mean variation across trials. Berlin, 
Santanna, Schmid, Szczech, and Feldman (2002) take this one step further by highlighting that 
the group-level (also called ‘ecological’) analysis that is achievable through meta-regressions 
may fail to identify important differences in the effect of treatment between two sub-groups. In 
all, the challenges of exclusively using primary study-level data in meta-analysis cannot be 
ignored. To account for these differences, a real change is needed in publishing practices. If 
researchers were to make patient-level data publicly available, we could account for the 
limitations described by Berlin et al. (2002), and better understand sub-groups that may be 
missed by broad aggregation at a primary study level. Moreover, we could develop more 
sophisticated models that account for patient demographics in relation to change. This would 
enable us to move away from the mean and potentially offer patients more than just an ‘average’ 
treatment. Such a shift in publishing practice will not happen overnight, but there has been some 
progress in making patient data more available. Perhaps the best example of this is the 
OpenTrials initiative (www.opentrials.net), led by Ben Goldacre. OpenTrials is a collaborative 
and open online database of information about clinical research trials around the world 
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(Goldacre & Gray, 2016). Such initiatives are in their infancy, but hold promise in easily 
enabling meta-analysis of patient level data.  
Until collaborations like OpenTrials are well established, the responsibility for 
gathering patient-level data might lie with the meta-analyst, who could contact authors of 
primary studies requesting patient-level data. Initial skepticism about potential response rates is 
understandable, and the consequent bias of only being able to analyse data from the self-
selecting sample of authors who share their data should not be overlooked. Indeed, there are 
infamous examples of trial teams being reluctant to share data. A recent example is the PACE-
trial, which investigated psychotherapy for chronic fatigue syndrome (White et al., 2011). 
Patient groups and academics had to spend considerable time and money requesting patient data 
through freedom of information requests before it was released. After secondary analysis, it 
became clear that the authors had deviated from their pre-stated protocol, which had led to 
inflated treatment effects (Geraghty, 2016). However, we must not let such examples deter us 
from attempting to synthesise patient-level information across trials. Indeed, there have been 
examples of such approaches being used with some success. For example, Vickers et al. (2012) 
were able to obtain patient data for 29 out of 31 relevant studies when they used meta-analysis 
of patient level data to explore the effects of acupuncture for chronic pain. While this movement 
is currently emerging as a trend, enabling wider access to patient-level data sets would allow 
even greater precision when inferring relationships between predictors such as dose of treatment 
and patient outcome.  
4.4.2 Implications for treatments 
The lack of adequate treatment descriptions makes it difficult to identify active 
ingredients in treatments. To continue to better understand the relationship between different 
treatment components and outcome, reporting of the specific treatment content must improve. It 
is insufficient to describe in a sentence or two what ‘CBT’ meant in the trial because such 
descriptions would not enable replications of treatment protocol. Studies that do not report 
treatment in such a way ought to be deemed low quality. It is also time to pause ‘bolting on’ 
additional treatment components, such as mindfulness, to existing treatment protocols. The 
research priority should be establishing the effectiveness of the components frequently used at 
the moment before adding further variations. 
One natural extension of this thesis would be to move toward a better understanding of 
the dose of each component. This was rarely reported in the primary studies included here, and 
when it was reported, it was usually for the exercise components only. Again, specific reporting 
about the amounts of each component may help us to understand whether there are specific 
components of treatment that help to bring about change more quickly. For example, one might 
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hypothesise that including lots of ‘problem solving’ toward the beginning of therapy might 
improve outcomes by equipping patients with the skills to resolve potential barriers that might 
otherwise have prevented them from continuing in therapy. There is, I acknowledge, an inherent 
difficulty here in that the underlying assumption of this point rests on the idea that one hour of 
treatment component A is equal to one hour of treatment component B. This is unlikely to be 
the case, but until we are able to breakdown the specific details of interventions that are 
delivered, our conclusions about whether all treatment components are created equal will be 
relegated to the realm of the vague and general. 
4.5 Implications for Clinical Practice 
The issue of dose is important for designing and managing clinical services. This thesis 
found that there was an association between the number of weeks over which the treatment was 
delivered and outcome, such that longer treatments resulted in larger improvements, at least for 
some outcomes. This suggests that although clinical services are under increasing pressure to 
see more clients in less time, clinicians need to be mindful that large change may take time. 
Having said this, there were examples where improvement was seen for relatively short 
psychological interventions. The implication here is a political one. In light of the evidence that 
has accumulated through this review and others (e.g. Waterschoot et al., 2014), NICE guidelines 
must go further than excluding any reference to minimum number of hours, and ought to clarify 
that a range of treatment hours are able to bring about a change – more than 100 hours are not 
necessarily needed to facilitate improvement.  
Early intervention may be important to consider. The average person included in the 
primary studies here had been living with pain for nearly ten years. I found some evidence that 
treatment effects were smaller the longer that participants had been living with pain. This 
suggests that if we can intervene earlier, we may be able to help people see greater benefits from 
psychological interventions. This is meaningful for clinical practice where psychological 
interventions are usually referred to as a last resort if a person continues to be in pain despite 
many years of searching for a medical ‘cure’. Perhaps if psychological interventions were 
brought earlier into the chronic pain treatment pathway, we might see larger effects.  
Finally, clinicians may be interested in the similarities between treatment components 
across different treatment types. For some clinicians this may fit with their experience of 
delivering psychological interventions for chronic pain. They might create their own ‘blend’ of 
psychological treatments by using the components that fit well for them, or that they think might 
be helpful to the client in front of them. Clinicians can play a key role in piecing together the 
fragmented approach to treatment components by building a body of practice-based evidence 
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(Margison et al., 2000). The single-case study design described earlier can be readily applied in 
routine clinical settings and could help learn more about the relevance of specific treatment 
components for outcome. 
4.6 Strengths of this Thesis 
A key strength of this thesis is that it is one of the largest reviews about the impact of 
psychological interventions for chronic pain to date. Indeed, I included nearly three times as 
many studies as previous meta-regressions in the field (Glombiewski et al., 2010; Hoffman et 
al., 2007). The breadth of studies included has meant that findings included a range of types of 
chronic pain and a range of treatment types. This is reflective of real-world clinical practice, and 
adds to the generalisability of my findings. For example, the inclusion of studies that had an 
active psychological intervention but were not facilitated by a psychologist (i.e. they were 
supervised or trained by a psychologist), adds to the generalisability of these findings with 
increasingly more psychological interventions being delivered by non-psychologists.  
Attrition rates were relatively low, suggesting that the findings here are generalisable 
beyond the ‘treatment completers’. Analysis of the quality of trials, as measured by the Yates 
Quality Rating Scale showed that quality of trials has improved over time, and risk of bias was 
moderately low. This adds credibility to the findings here.   
The main pitfall of meta-regression analyses has been described as ‘data-dredging’ 
(Thompson & Higgins, 2002), where so many analyses are run that spurious findings are 
generated. While it would be possible that some of the findings presented here are spurious, 
there are two reasons to believe that they are not. The first is that they are broadly comparable 
with previous research, such as the reviews by Williams et al. (2012) and Waterschoot et al. 
(2014). The second is that I limited the number of analyses that I conducted, analysing only 
three out of nine participant characteristics that I extracted data about. This suggests the number 
of false positive results should be limited. 
4.7 Limitations of this Thesis 
I have already discussed several limitations and challenges of this thesis. In this section, 
I focus on the limitations of developing treatment components, aggregating across outcome 
measures and teasing apart efficacy and effectiveness.  
4.7.1 Developing treatment components  
A challenge to creating the treatment component categories was that the information 
was extracted from the published research papers. Descriptions of the specific content of 
treatments may not be well represented in trial write-ups. Although this is a problem is not 
limited to the field of psychological interventions for chronic pain, it does present a problem for 
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meta-analytic exploration of treatment components. It may well be that components were 
included in treatments but were not reported. This means that the treatment categories are only 
as precise as the descriptions of treatment content in trials.  A more robust approach to 
extracting information about treatment components would have been to request a copy of the 
treatment protocol from authors. This was beyond the scope of this thesis, but may be a helpful 
strategy for future research and would help to further shine light on the discrepancies between 
what might be delivered and what is reported. It also reinforces the importance of 
comprehensively reporting treatment protocols. In theory, one’s treatment protocol should be 
descriptive enough that it could be replicated by others, but this was rarely the case. Exceptions 
to this were where authors included a table of components and how they were defined. Kerns et 
al. (2014) reported something similar in their trial, which was a list of treatment ‘modules’ such 
as relaxation or pacing, and provided a brief description about what this meant. Such a detailed 
approach to reporting treatments might be considered as best practice.  
A second criticism of my analysis lies with the ‘bottom up’ approach to exploring 
treatment components. This approach meant that trials that were more commonly included may 
have skewed the final list of treatment components. One might argue that because of the 
dominance of CBT in trials of psychological interventions for chronic pain, that the treatment 
components that I have created are overly CBT focused. I would argue that the fact that a high 
proportion of non-CBT trials included these components confirms that the final list of treatment 
components did not overly represent components used in CBT. For example, problem solving 
could be used in ACT or a multidisciplinary group, as well as CBT. This suggests that the 
‘bottom-up’ approach, while not perfect, was a reasonable approach to categorising treatment 
content. An alternative approach would be a Delphi study to explore categorise content in a 
‘top-down’ manner (Cantrill, Sibbald, & Buetow, 1996). This would involve surveying a panel 
of experts in the field and gathering their thoughts on what a potential list of treatment 
components may be comprised of. This would be a valuable avenue for further research, and the 
list generated here might present a helpful starting block. 
4.7.2 Outcome measures 
The variety of outcome measures used across trials of psychological interventions for 
chronic pain has been well documented, and has led to recommendations regarding which 
outcome measures should be included in trials (Turk et al., 2003). Rather than selecting only 
one outcome measure per study, I created aggregated outcome domains by combining results 
across different measures of the same construct. However, this is not a perfect solution to the 
challenge of outcome heterogeneity. One problem that this may cause is that outcome domains 
may not be truly independent of each other. For example, I categorised quality of life measures 
as assessing ‘physical functioning’. Although this is in line with previous attempts to group 
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measures into outcome domains (Fenton & Morley, 2013), it is an over-simplistic representation 
of what a quality of life measure actually assesses. One might be functioning relatively well 
physically, but have a low score on a quality of life measure because of difficulties with low 
mood and anxiety. This means that the low quality of life score actually reflects difficulties with 
emotional functioning, rather than physical functioning. It may be important to remember, 
therefore, that while outcome domains are a helpful way of including more data from included 
studies, they represent a broad range of outcome measures and are unlikely to be totally 
independent of each other.   
Furthermore, almost all outcome measures used in primary studies were self-report. 
This may have introduced bias in several ways. Patients may perceive themselves as changing 
more or less than they have actually changed. Alternatively, they may wish to present 
themselves as having changed because of social desirability bias; a tendency to choose 
responses that others are most likely to approve of (van de Mortel, 2008).  Having said this, it is 
possible that self-report measures should not cause too much concern. In a meta-regression of 
psychotherapy for depression, Cuijpers, Li, Hofmann, and Andersson (2010) compared self-
reported and clinician-reported change. They found that clinicians reported greater 
improvements than patients (i.e. the clinicians’ effect sizes were inflated). This suggests that the 
results from self-report may be a conservative estimate of improvement. In addition, I would 
argue that it is the patient’s perception of whether they have changed that is most important, 
rather than attempting to identify some measure of ‘true’ change.  
4.7.3 Efficacy, but not necessarily effectiveness 
An important distinction should be made between efficacy and effectiveness. Nathan, 
Stuart, and Dolan (2000) describe efficacy as the evaluation of treatment effects under 
conditions of high internal validity (i.e. highly controlled studies). Whereas effectiveness is the 
evaluation of treatment effects under conditions of high external validity (i.e. less controlled and 
more similar to routine clinical practice). I only included RCTs in this review. RCTs are the 
‘gold standard’ approach to test efficacy. Although my findings point to the need for further 
evaluation of treatment fidelity, and perhaps more scrutiny of treatment manuals, there is a 
wealth of RCTs that have consistently demonstrated positive (albeit modest) effects for 
psychological interventions for chronic pain. This means that we can be confident psychological 
treatments are efficacious as treatment approaches. However, the exclusion of trials that were 
not RCTs means that we may be less confident in our ability to comment on the effectiveness of 
the trials. Coupled with this is the issue that the measure of magnitude of change that is used in 
meta-analysis, the effect size, relates only to statistical change. We can say little (if anything) 
about how this might relate to clinically significant change. 
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A separate but related point is that I only included trials that had been published in peer 
reviewed journals. There are several ways in which excluding unpublished studies limits this 
thesis. First, it may be that there is an over-representation of certain types of chronic pain, and / 
or certain types of treatment. Perhaps most notably, the frequency of CBT may not be purely 
attributable to its popularity, rather it may be that CBT trials were more likely to receive funding 
and be published. Consequently, other therapeutic modalities may be poorly represented in the 
trials included here, or not represented at all. For example, anecdotally, clinicians might talk 
about using models such as Cognitive Analytic Therapy (Ryle, Poynton, & Brockman, 1990) or 
Compassion Focused Therapy (Gilbert, 2009), but these modalities do not seem to have 
appeared in peer-reviewed publications. Secondly, we must be careful not to consider the peer-
review process a panacea to issues of bias, quality and availability of evidence. As Glass, the 
founder of meta-analysis, explained at a conference; “It is one thing to believe that peer review 
guarantees truth; it is quite another to believe that all truth appears in peer reviewed journals” 
(Glass, 2000). Having said that, Veehof et al. (2011) included both published and unpublished 
trials in their meta-analysis of psychological interventions for chronic pain and found inflated 
effect sizes for unpublished studies in comparison with published studies. Although Veehof et 
al. is just one review, it suggests that restricting the inclusion criteria to only include published 
studies may have resulted in a conservative estimate of effect. Nonetheless, we must not negate 
the potential for unpublished studies to have an important contribution to understanding whether 
all treatment components are created equal. In sum, this means that the findings should be 
cautiously generalised to ‘real-world’ clinical settings.  
4.8 Conclusion 
The aim of this thesis was to explore two questions:  
1. Is dose related to outcome in psychological interventions for adults with chronic 
pain?  
2. What are the core components of treatment being delivered in psychological 
interventions for chronic pain, and how do they differ between types of 
intervention? 
This thesis goes some way to establishing that there does not seem to be a linear 
relationship between dose and outcome. It seems as though there are differential relationships 
between dose (measured in weeks) and certain outcome measures. These findings reinforce the 
complex process of helping patients who have been living with chronic pain. One striking 
finding from this thesis is the lack of consistency in the components of treatment delivered by 
the ‘same’ psychological intervention used across trials, coupled with considerable overlap in 
the components used by ‘different’ interventions.  
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I have pointed to several potential implications of this work. Perhaps the most important 
will be the further investigation of dose-response relationships through the use of single-case 
designs and analysis of patient level data to test the hypotheses generated here. Another 
important implication is that we ought to clarify current NICE guidelines, which have currently 
removed any reference to the important issue of treatment dose. I suggest that it should be 
clarified that there is no evidence to support a minimum number of hours required for 
psychological interventions to be effective.  
So, are all treatment components created equal? In short, no. No relationship was 
established between dose in hours and outcome, but some relationships were found for dose in 
weeks and outcome. Even then, dose in weeks was not equally able to bring about improvement 
across all outcome domains. Coupled with this, it seems as though there are patient 
characteristics, such as pain duration, that may affect the extent to which treatment can bring 
about change. Taken together, it would appear unlikely that there is one ‘optimal’ treatment for 
everyone living with chronic pain. Alternative and more flexible research designs are needed to 
enable a better understanding of how participant characteristics and treatment components 
interact. Until then, we will be limited in our ability to consider ‘optimal’ approaches to 
personalising treatments.  
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Appendices 
Appendix A. MeSH Terms Search Strategy 
MEDLINE search strategy (via OVID)  
1. PAIN explode all trees (MeSH)  
2. (chronic* near pain*) 
3. (#1 and (chronic* near pain*))  
4. (chronic* near discomfort)  
5. (chronic* near ache*) 
6. (chronic* near fibromyalgia:ab) 
7. (chronic* near fibromyalgia:ti) 
8. (chronic* near neuralgi*:ab) 
9. (chronic* near neuralgi*:ti) 
10. (chronic* near dysmenorrhea:ti) 
11. (chronic* near dysmenorrhea:ab) 
12. (chronic* near dysmenorrhoea:ti) 
13. (chronic* near dysmenorrhoea:ab) 
14. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13)  
15. PSYCHOTHERAPY explode tree 1 (MeSH) 
16. COGNITIVE THERAPY single term (MeSH) 
17. BEHAVIOR THERAPY explode tree 1 (MeSH) 
18. BIOFEEDBACK (PSYCHOLOGY) single term (MeSH) 
19. ((behaviour* next therapy) or (behaviour* next therapies)) 
20. ((cognitive next therapy) or (cognitive next therapies))  
21. (relax* near technique*) 
22. ((relax* near therapy) or (relax* near therapies)) 
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23. meditat* 
24. psychotherap* 
25. (psychological next treatment) 
26. ((psychological next therapy) or (psychological next therapies)) 
27. (group next therapy) 
28. (self-regulation next training) 
29. (coping next skill*) 
30. (pain-related next thought*) 
31. (behaviour* near rehabilitat*) 
32. (psychoeducation* next group) 
33. (psychoeducation* next groups) 
34. (psycho-education* next groups) 
35. (psycho-education* next group) 
36. (mind and (body next relaxation next technique*)) 
37. MIND-BODY AND RELAXATION TECHNIQUES explode tree 1 (MeSH) 
38. (#15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or 
#28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37) 
39. (#14 and #38)  
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Appendix B. Comprehensive Meta-analysis Results Table for Active Treatment Compared with Active Control. 
Active treatment vs. active control  
Outcome Domain 
No. of 
Studies 
No. of 
Participants 
Effect Size 
(Hedges' g) 
Standard 
Error 
t Sig Lower CI Upper CI I2 !" 
Pain Experience 38 1712 0.31 0.16 1.97 0.057 -0.01 0.63 99.83% 0.949 
Pain Behaviour  12 608 0.28 0.12 2.27 0.044 0.01 0.55 98.04 0.176 
Emotional Functioning 35 1611 0.27 0.11 2.51 0.017 0.05 0.50 99.36 0.412 
Physical Functioning 38 1701 0.31 0.13 2.35 0.024 0.04 0.58 99.56 0.665 
Coping & Cognitive Appraisal 24 1073 0.58 0.35 1.65 0.112 -0.15 1.30 100 2.938 
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Appendix C. Comprehensive Meta-analysis Results Table for Active Treatment Compared with TAU / WLC 
Active treatment vs. TAU / WLC 
Outcome Domain 
No. of 
Studies 
No. of 
Participants 
Effect Size 
(Hedges' g) 
Standard 
Error 
t Sig Lower CI Upper CI I2 !" 
Pain Experience 28 1398 0.39 0.20 1.95 0.062 -0.02 0.81 99.94 1.139 
Pain Behaviour  5 197 0.36 0.10 3.56 0.024 0.08 0.64 96.57 0.475 
Emotional Functioning 25 1234 0.24 0.08 3.24 0.003 0.09 0.40 99.18 0.139 
Physical Functioning 28 1402 0.12 0.06 2.11 0.044 0.00 0.23 98.12 0.084 
Coping & Cognitive Appraisal 17 127 0.38 0.08 4.92 0.000 0.22 0.54 98.93 0.098 
 
